CN105753817A - 一类取代氮杂环衍生物及其应用 - Google Patents
一类取代氮杂环衍生物及其应用 Download PDFInfo
- Publication number
- CN105753817A CN105753817A CN201511024626.7A CN201511024626A CN105753817A CN 105753817 A CN105753817 A CN 105753817A CN 201511024626 A CN201511024626 A CN 201511024626A CN 105753817 A CN105753817 A CN 105753817A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- heteroaryl
- heterocyclic radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000623 heterocyclic group Chemical class 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 245
- 239000003814 drug Substances 0.000 claims abstract description 79
- 210000004185 liver Anatomy 0.000 claims abstract description 50
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 23
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims abstract description 22
- 108010028554 LDL Cholesterol Proteins 0.000 claims abstract description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 15
- 201000005577 familial hyperlipidemia Diseases 0.000 claims abstract description 14
- 230000007850 degeneration Effects 0.000 claims abstract description 13
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 11
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 10
- 208000008589 Obesity Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 9
- 238000008214 LDL Cholesterol Methods 0.000 claims abstract description 7
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims abstract 2
- -1 heterocyclic radical Chemical group 0.000 claims description 194
- 125000000217 alkyl group Chemical group 0.000 claims description 83
- 125000003118 aryl group Chemical group 0.000 claims description 78
- 125000001424 substituent group Chemical group 0.000 claims description 71
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 66
- 125000001072 heteroaryl group Chemical group 0.000 claims description 63
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 55
- 125000000304 alkynyl group Chemical group 0.000 claims description 54
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 47
- 238000006243 chemical reaction Methods 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 44
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 39
- 125000003545 alkoxy group Chemical group 0.000 claims description 38
- 239000003153 chemical reaction reagent Substances 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 38
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 150000002632 lipids Chemical class 0.000 claims description 35
- 239000007858 starting material Substances 0.000 claims description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 31
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 29
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 28
- 239000012453 solvate Substances 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 26
- 238000005859 coupling reaction Methods 0.000 claims description 23
- 229910052799 carbon Chemical group 0.000 claims description 21
- 210000002381 plasma Anatomy 0.000 claims description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 125000001544 thienyl group Chemical group 0.000 claims description 16
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 15
- 125000001624 naphthyl group Chemical group 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 14
- 125000005493 quinolyl group Chemical group 0.000 claims description 14
- 125000002541 furyl group Chemical group 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 claims description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 230000004060 metabolic process Effects 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 10
- 238000010168 coupling process Methods 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 229950002366 nafoxidine Drugs 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- 125000005936 piperidyl group Chemical group 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 7
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 6
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 6
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 claims description 6
- 239000010238 camphora Substances 0.000 claims description 6
- 229940025250 camphora Drugs 0.000 claims description 6
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims description 6
- 125000005504 styryl group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 238000011287 therapeutic dose Methods 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 33
- 102000000853 LDL receptors Human genes 0.000 abstract description 21
- 108010001831 LDL receptors Proteins 0.000 abstract description 21
- 230000014509 gene expression Effects 0.000 abstract description 16
- 235000012000 cholesterol Nutrition 0.000 abstract description 12
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 222
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 138
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- 238000001819 mass spectrum Methods 0.000 description 87
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 75
- 239000002585 base Substances 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 239000000047 product Substances 0.000 description 45
- 238000004809 thin layer chromatography Methods 0.000 description 37
- 239000007787 solid Substances 0.000 description 34
- 230000000694 effects Effects 0.000 description 33
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 31
- 239000003925 fat Substances 0.000 description 31
- 238000005406 washing Methods 0.000 description 31
- 235000019197 fats Nutrition 0.000 description 30
- 238000003756 stirring Methods 0.000 description 30
- 239000008280 blood Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 27
- 238000012544 monitoring process Methods 0.000 description 27
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 108010007622 LDL Lipoproteins Proteins 0.000 description 25
- 102000007330 LDL Lipoproteins Human genes 0.000 description 25
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- 208000031226 Hyperlipidaemia Diseases 0.000 description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 23
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 210000003494 hepatocyte Anatomy 0.000 description 17
- 238000000605 extraction Methods 0.000 description 16
- 0 CC(C)(C)OS(*)(=N*)=O Chemical compound CC(C)(C)OS(*)(=N*)=O 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 231100000240 steatosis hepatitis Toxicity 0.000 description 15
- 208000004930 Fatty Liver Diseases 0.000 description 14
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 14
- 206010019708 Hepatic steatosis Diseases 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 14
- 208000010706 fatty liver disease Diseases 0.000 description 14
- 239000000376 reactant Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 208000035126 Facies Diseases 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 11
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 208000029078 coronary artery disease Diseases 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 229960002855 simvastatin Drugs 0.000 description 9
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 7
- 229940122392 PCSK9 inhibitor Drugs 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 7
- 229940093265 berberine Drugs 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 229960004106 citric acid Drugs 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical group FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 101150094724 PCSK9 gene Proteins 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 5
- 229940125753 fibrate Drugs 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 239000012053 oil suspension Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229940126586 small molecule drug Drugs 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- ALBQXDHCMLLQMB-UHFFFAOYSA-N 4-phenylbenzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1C1=CC=CC=C1 ALBQXDHCMLLQMB-UHFFFAOYSA-N 0.000 description 3
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 3
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108010018763 Biotin carboxylase Proteins 0.000 description 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 3
- 239000012964 benzotriazole Substances 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000010338 boric acid Nutrition 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 description 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 125000005945 imidazopyridyl group Chemical group 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- WCPFQQHADRJANG-UHFFFAOYSA-N 1-(4-methoxyphenyl)cyclopropane-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1(C(O)=O)CC1 WCPFQQHADRJANG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XQJAHBHCLXUGEP-UHFFFAOYSA-N 2-bromo-1-(4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(=O)CBr)C=C1 XQJAHBHCLXUGEP-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FZAGOOYMTPGPGF-UHFFFAOYSA-N Lambertine Chemical compound C1=C2C3=CC4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 FZAGOOYMTPGPGF-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- 108010044159 Proprotein Convertases Proteins 0.000 description 2
- 102000006437 Proprotein Convertases Human genes 0.000 description 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000004171 alkoxy aryl group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960000815 ezetimibe Drugs 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108010094020 polyglycine Proteins 0.000 description 2
- 229920000232 polyglycine polymer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000005306 thianaphthenyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- IOQORVDNYPOZPL-VQTJNVASSA-N (5S,6R)-5-(4-chlorophenyl)-6-cyclopropyl-3-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-5,6-dihydro-2H-1,2,4-oxadiazine Chemical compound ClC1=CC=C(C=C1)[C@@H]1NC(=NO[C@@H]1C1CC1)C1=NC(=C(C=C1)N1C=NC(=C1)C)OC IOQORVDNYPOZPL-VQTJNVASSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- NMGLVHXJOMBIJW-UHFFFAOYSA-N 1h-benzimidazole;dihydrochloride Chemical compound Cl.Cl.C1=CC=C2NC=NC2=C1 NMGLVHXJOMBIJW-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical compound C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- FFPAFDDLAGTGPQ-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)acetic acid Chemical compound COC1=CC(CC(O)=O)=CC(OC)=C1 FFPAFDDLAGTGPQ-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MCFBUIIRFZBRCU-UHFFFAOYSA-N 4-[1-[5-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyridin-2-yl]piperidin-4-yl]oxycyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1OC1CCN(C=2N=CC(=CC=2)C=2NC3=CC(=CC=C3N=2)C(F)(F)F)CC1 MCFBUIIRFZBRCU-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- UICBHOXXGLYZJH-UHFFFAOYSA-N 5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium Chemical compound C1=CC=C2CC[N+]3=CC4=CC=CC=C4C=C3C2=C1 UICBHOXXGLYZJH-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- SDZGDZAAZKIUJB-UHFFFAOYSA-N C1C2(C3)C1CC3C2 Chemical compound C1C2(C3)C1CC3C2 SDZGDZAAZKIUJB-UHFFFAOYSA-N 0.000 description 1
- PTDNVRMMBUPVLP-UHFFFAOYSA-N C1CC(C2=NNC3=C2N=CC=C3)=CC1 Chemical compound C1CC(C2=NNC3=C2N=CC=C3)=CC1 PTDNVRMMBUPVLP-UHFFFAOYSA-N 0.000 description 1
- IXEPCAMIVCTJJM-UHFFFAOYSA-N C1CN1N1CCC1 Chemical compound C1CN1N1CCC1 IXEPCAMIVCTJJM-UHFFFAOYSA-N 0.000 description 1
- GKQXUVROVINIDJ-UHFFFAOYSA-N CC(CC1)=CC=C1[S+]=C Chemical compound CC(CC1)=CC=C1[S+]=C GKQXUVROVINIDJ-UHFFFAOYSA-N 0.000 description 1
- UVADEDSZNUWFGH-UHFFFAOYSA-N CC(CC1)=CC=C1[S+]=O Chemical compound CC(CC1)=CC=C1[S+]=O UVADEDSZNUWFGH-UHFFFAOYSA-N 0.000 description 1
- QMFJIJFIHIDENY-UHFFFAOYSA-N CC1=CC=CCC1 Chemical compound CC1=CC=CCC1 QMFJIJFIHIDENY-UHFFFAOYSA-N 0.000 description 1
- NZRCUMOTNXTCQP-UHFFFAOYSA-N CCC(CC(CC(N1CCC(CC2=CCC(CCCC(C3C=CC(CC)=CC3)=N)C=C2)CC1)=O)CC1)=C1[OH3+3]C Chemical compound CCC(CC(CC(N1CCC(CC2=CCC(CCCC(C3C=CC(CC)=CC3)=N)C=C2)CC1)=O)CC1)=C1[OH3+3]C NZRCUMOTNXTCQP-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- GQMHDJQMMXYIMX-UHFFFAOYSA-N CCc(cc1)ccc1N(CC1)CCN1C(C1NC=CC=C1)O Chemical compound CCc(cc1)ccc1N(CC1)CCN1C(C1NC=CC=C1)O GQMHDJQMMXYIMX-UHFFFAOYSA-N 0.000 description 1
- GLJGLGNGUCOPBJ-UHFFFAOYSA-N CCc(cc1)ccc1N1CCNCC1 Chemical compound CCc(cc1)ccc1N1CCNCC1 GLJGLGNGUCOPBJ-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000113306 Monascus purpureus Species 0.000 description 1
- 235000002322 Monascus purpureus Nutrition 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- SUKXKLNDBLNTSW-UHFFFAOYSA-N N-(4-hydroxycyclohexyl)-6-phenylhexanamide Chemical compound OC1CCC(CC1)NC(CCCCCC1=CC=CC=C1)=O SUKXKLNDBLNTSW-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- 101800000021 N-terminal protease Proteins 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- UAPCKORZDAFJAB-UHFFFAOYSA-N OC(c1ccccn1)O Chemical compound OC(c1ccccn1)O UAPCKORZDAFJAB-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229940123185 Squalene epoxidase inhibitor Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- NRAINUFKKPBZQY-UHFFFAOYSA-N [O]C1CC1 Chemical compound [O]C1CC1 NRAINUFKKPBZQY-UHFFFAOYSA-N 0.000 description 1
- GYAPJISEIGCPQO-UHFFFAOYSA-N [O]C1CCC1 Chemical compound [O]C1CCC1 GYAPJISEIGCPQO-UHFFFAOYSA-N 0.000 description 1
- DWDAZFJBSZTCCM-UHFFFAOYSA-N [O]C1CCCCC1 Chemical compound [O]C1CCCCC1 DWDAZFJBSZTCCM-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- FZZIXIYLIAIOOE-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1.C1=CC=CC2=CC=CC2=C1 FZZIXIYLIAIOOE-UHFFFAOYSA-N 0.000 description 1
- 229960001264 benfluorex Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CJAVTWRYCDNHSM-UHFFFAOYSA-N benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester Chemical compound C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 description 1
- FBOSKQVOIHEWAX-UHFFFAOYSA-N benzothiazine Chemical compound C1=CC=C2N=CCSC2=C1 FBOSKQVOIHEWAX-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OJVABJMSSDUECT-UHFFFAOYSA-L berberin sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 OJVABJMSSDUECT-UHFFFAOYSA-L 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical group C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical group 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 208000016332 liver symptom Diseases 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- OPECTNGATDYLSS-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 OPECTNGATDYLSS-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- XIUROWKZWPIAIB-UHFFFAOYSA-N sulfotep Chemical compound CCOP(=S)(OCC)OP(=S)(OCC)OCC XIUROWKZWPIAIB-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 108010002139 very low density lipoprotein triglyceride Proteins 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/18—[b, e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及式(V)化合物和制备方法及其在医药上的应用。具体而言,本发明涉及通式为(V)化合物的衍生物和制备方法以及其作为治疗剂,在预防和治疗高脂血症,高胆固醇血症,高甘油三酯血症,肝脂肪变性,II型糖尿病,高血糖症,肥胖症或胰岛素抵抗症,代谢综合征,抗肿瘤药物中的用途。本文公开的化合物还能降低总胆固醇,LDL-胆固醇和甘油三酯,并且增加肝LDL受体表达,抑制PCSK9表达。
Description
技术领域
本发明的技术涉及用于治疗高脂血症(包括高甘油三酯血症和高胆固醇血症),肝脂肪变性,II型糖尿病,高血糖症,胰岛素抵抗症,肥胖症,代谢综合征和抗肿瘤中的用途、化合物和组合物。
背景技术
代谢综合征(MetabolicSyndrome,MS)是多种代谢成分异常聚集的病理状态,是一组复杂的代谢紊乱症候群,是导致糖尿病,心脑血管疾病的危险因素。
心脑血管疾病是危害人类健康的头号杀手,其病因非常复杂,高血脂又作为其非常关键的危险因子而受到大多数人的关注,而且随着生活水平的改善和老龄化的加速,高血脂症的发生率与死亡率明显提升,更有相关文献报道,血脂异常是引起动脉粥样硬化、冠心病、心肌梗死等的主要原因。
高血脂症常被解释为:脂肪的代谢或者运转异常使得血浆中一种或多种脂质高于正常。而且高血脂症是种全身性的疾病,通常指血清中总胆固醇(TC),甘油三酯(TG)过高或高密度脂蛋白胆固醇(HDL-C)过低,现代医学称之为血脂异常。脂质是不溶或微溶于水,所以必须与蛋白质结合形成脂蛋白,因此,高血脂症通常也称为高脂蛋白血症。
高血脂与脑梗塞:血液中胆固醇增高容易形成动脉硬化斑块,当这些斑块在动脉壁内堆积时,会使得动脉官腔狭窄,阻塞血液流入相应的部位,便会引起动能缺损。当它发生在脑血管时就会引起脑梗塞,医学证明:长期调脂治疗不仅能治疗脑梗塞,还能预防脑梗塞。
高血脂与冠心病:冠心病也叫作冠状动脉粥样硬化性心脏病。冠状动脉是给心脏供血的主要动脉,若过多的脂肪沉积,便会造成动脉硬化,从而使血流受阻,引起心脏缺血,发生一系列的症状,即冠心病。引起冠心病的危险因素很多,如:高血脂、吸烟、肥胖、高血压、缺乏体力活动、糖尿病、冠心病家族史等,其中、高血脂又是引起冠心病的重要危险因素之一。所以防治冠心病最基本的疗法是调节血脂,研究表明血清中总胆固醇水平下降1%,则冠心病发生率下降2%。长期配合调脂治疗能够减少冠心病的心绞痛、心肌梗死等的发生率和死亡率。
高血脂与脂肪肝:脂肪肝是指脂肪在肝内大量积累所致,常伴随血脂增高。脂肪肝发病率高达5-10%,成人体内转氨酸增高者大约35%都是脂肪肝,部分严重患者可发展为肝硬化。因此,脂肪肝治疗也应进行调脂的治疗。
高血脂与糖尿病:高血压、高血脂与高血糖常被称为“三高”,是威胁糖尿病患者身体健康的主要因素。三者密切相关,高血脂可以加重糖尿病的症状,大多数糖尿病患者伴有高血脂,更易导致脑中风、冠心病、肢体坏死、眼底病变、肾脏病变、神经病变等,因此糖尿病患者除治疗高血糖外,还应注意调血脂,这对于减少糖尿病患者死亡率和致残率是非常重要。
高血脂症定义为血脂紊乱或血脂异常。通常指人体内血脂浓度超出了正常范围。包括甘油三酯(TG)、血清总胆固醇(TC)、极低密度脂蛋白胆固醇(VLDL-C)或低密度脂蛋白胆固醇(LDL-C)水平升高和高密度脂蛋白胆固醇(HDL-C)水平降低随着高血脂与心血管疾病的深入研究,人们开始认识到降血脂对减少心血管疾病的风险具有非常重要的意义。
现在市场上常用的降血脂药物主要有他汀类、贝特类、烟酸类、胆酸螯合剂类等。
他汀类代表药物:阿托伐他汀,辛伐他汀,洛伐他汀,普伐他汀,氟伐他汀等。这类药物是近年来发展比较快的降脂药物,主要是抑制血清总胆固醇(TC)合成途径中的限速酶3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶的活性,降低TC合成;使得低密度脂蛋白受体数量增加,加快LDL降解,同时增加HDL含量,有利于TC的清除和转运。
不足之处:其所带来的副作用是不可避免的,如:横纹肌溶解,肌炎以及肝脏的各种酶活性增强等,另外有一些患者未能很好的适应他汀类药物的治疗,更重要的是单一的他汀类治疗往往还不能达到预期的理想效果。
贝特类代表药物:氯贝丁酯,吉非罗齐,非诺贝特等。该类药物经过长期的临床应用,已经被证明是一类耐受性好、具有好的调脂作用的药物。其降脂途径除了和他汀类相似外还有增加脂蛋白脂酶的活性,使甘油三酯(TG)的清除增加;降低血糖,从而使得乙醜辅酶A与游离脂肪酸趋向于葡萄糖的合成,使脂质合成减少。
不足之处:消化道常出现不良反应,偶尔会出现过敏反应,视力障碍,由于该类药物增加了胆固醇在胆汁中浓度,所以还可能引起胆结石。
烟酸类代表药物:烟酸,烟酸肌醇酯,阿昔莫司等。这类药物主要通过抑制脂肪的分解和游离脂肪酸的形成,抑制肝脏合成甘油三酯(TG)和极低密度脂蛋白(VLD-L)来降低血脂。
不足之处:对糖尿病患者降血脂作用不明显,副作用如:肝中毒,高血糖较为明显,常出现皮疫,瘙痒等不良反应。
胆酸螯合剂类代表药物:依折麦布(Ezetimibe),多稀不饱和脂肪酸等。这类降脂药物可以分为胆固醇吸收抑制剂和多稀不饱和脂肪酸两类。
(1)、胆固醇吸收抑制剂(依折麦布):与胆汁酸结合,阻碍胆汁酸的重吸收,从而促使胆固醇转化为胆汁酸,在肠道和该药物结合排出体外。
(2)、多烯不饱和脂肪酸:与胆固醇结合为酯类,促进胆固醇降解为胆汁酸随胆汁排泄,从而使血柴总胆固醇的浓度降低。
低密度脂蛋白(LDL)水平过高能致动脉粥样硬化,降低血浆LDL水平对预防和治疗心脑血管等疾病具有重要的意义。血液中大约70%的LDL是通过低密度脂蛋白受体(LDLR)介导的内吞作用完成清除的,LDLR的表达受到前蛋白转化酶枯草杆菌蛋白酶/kexin9型(proproteinconvertasesubtilisin/kexintype9)(PCSK9)的影响,PCSK9是一个丝氨酸蛋白酶,主要在肝脏合成,它能够减少肝细胞中LDLR数量。PCSK9与位于细胞表面的LDLR结合后,内化至细胞里,促进溶酶体中LDLR降解。抑制PCSK9的活性可以增加LDLR数量,降低血浆中LDL水平。
PCSK9抑制剂的开发是当今大型跨国制药公司努力研发新型心血管疾病药物的重要方向,期待这类药物超越他汀类成熟的降脂药物。大型制药公司正密锣紧鼓地推动PCSK9抑制剂药物开发工作,目前的研究工作主要集中在生物制品药物(包括蛋白药物和长链核酸药物)的开发(如下表),生物制品药物与小分子药物针对治疗同一病症时,生物药具有成本高昂,只能采用注射制剂等有限的制剂方式等缺点,目前,还没有小分子PCSK9抑制剂成为临床候选药物。
目前公开了一系列PCSK9抑制剂的小分子化合物专利申请,其中包括WO2010075469,WO2011006000,WO2011051961,WO2011152508,WO2012090220,JP2013136572,WO2013132509,WO2013137371,WO2014017569,WO2014002105,WO2014002106,WO2014150326,WO2014150395,WO2014139008等。
尽管目前已经公开了一系列的具有抑制PCSK9表达和降脂效果的化合物,但是,仍然需要开发新的具有更好药效,药代结果的化合物,经过不断努力,本发明设计具有通式(V)结构的化合物并发现具有此类结构的化合物表现出优异的效果和作用,在更大范围内,更加深入和全面地揭示和阐明了结构和活性效能的关系,具有重要的应用价值。
发明内容
本发明的目的在于提供一种通式(V)所示化合物,以及它们的互变异构体、对映体、非对映体、消旋体和可药用的盐,以及代谢产物和代谢前体或前药。式V的化合物
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类;其中:
Y选自环烷基、杂环基、芳基、杂芳基,其中,
所述的环烷基、杂环基、芳基、杂芳基各自进一歩被一个或多个选自氢,卤,-OH,-NR′R″,-NO2,-Si(R′)3,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,-S(O)mR′,-S(O)nNR′R″,-OS(O)nR′,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″,-S(O)nNH(C=O)NR′R″,-NR′S(O)nR″,-NR′S(O)nNR′R″,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基的取代基所取代;
R1,R2,R3,R4,R5,R6,R7,R8独立地是氢,卤,经取代的或未经取代的硅基,氨基,硝基,氧代基,硫基,砜基,氰基,羰基,磺酰氧基,磷酰氧基,烷基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
M为氮原子,或者碳原子;
W为氮原子,或者碳原子;
K为-O-,-S-,-NH-,-CR5R6-,-C(O)-,-C(O)O-,-C(O)NH-,-SO2O-,-SO2-,-SO2NH-,-P(O)R5R6;
Z为-O-,-S-,-NH-,-CR5R6-,-C(O)O-,-C(O)NH-,-SO2O-,-SO2NH-,或者Z不为任何原子(即是,与Z相联的两个基团直接通过化学键连接);
环X为3~10元环,所述的3~10元环X选自环烷基、杂环基、芳基、杂芳基,其中,
所述的环烷基、杂环基、芳基、杂芳基各自独立地被一个或多个选自氢,卤,-OH,-NR′R″,-NO2,-Si(R′)3,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,-S(O)mR′,-S(O)nNR′R″,-OS(O)nR′,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″,-S(O)nNH(C=O)NR′R″,-NR′S(O)nR″,-NR′S(O)nNR′R″,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基的取代基所取代;
R′和R″独立的是氢或者经取代的或未经取代的烷基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基,
在-NR′R″,-C(O)NR′R″,-OC(O)NR′R″,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″中,其中NR′R″可以为4至20元含氮杂环基;
m=0,1,2;
n=1,2,3;
p=1,2,3;
q=0,1,2,3,4,5,6;
s=0,1,2;
t=0,1,2。
本发明涉及通式化合物化合物(V),其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中包括通式化合物化合物(VI),
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中:
R9,R10,R11,R12,R13,R14,R15,R16独立地是-H,卤,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R5,R6,R7,R8,Z,M,K,q,t,环X和环Y同前文所述。
本发明涉及通式化合物化合物(V),其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中包括通式化合物化合物(VII),
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中:
R9,R10,R11,R12,R13,R14,R15,R16独立地是氢,卤,经取代的或未经取代的硅基,氨基,硝基,氧代基,硫基,砜基,氰基,羰基,磺酰氧基,磷酰氧基,烷基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R17,R18,R19,R20,R21独立地是氢,卤,-OH,-NR′R″,-NO2,-Si(R′)3,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,-S(O)mR′,-S(O)nNR′R″,-OS(O)nR′,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″,-S(O)nNH(C=O)NR′R″,-NR′S(O)nR″,-NR′S(O)nNR′R″,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基;
R5,R6,R7,R8,R′,R″,K,Z,环X,M,m,n,q,r同前文所述。
本发明涉及通式化合物化合物(VII),其中,R9,R10,R11,R12,R13,R14,R15,R16独立地是-H,卤,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R17,R18,R19,R20,R21独立地是-H,卤,-OH,-NO2,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,取代的或未经取代的氨基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基,还选自包括:
R27选自苯基,C1-6烷基,环(C3-8)烷基,噻吩基,呋喃基,咪唑基,吡啶基,嘧啶基,哒嗪基,喹啉基,异喹啉基,苯乙炔基,苯甲基,苯乙烯基,萘基,取代氨基,吗啉基,哌啶基,N-甲基哌嗪基,四氢吡咯基,六氢吡啶基,樟脑烷基,对甲苯基,
其中,C1-6烷基任选被0至13个取代基取代,
噻吩基,呋喃基和咪唑基任选被0至3个取代基取代,
吡啶基任选被0至4个取代基取代,
嘧啶基和哒嗪基任选被0至3个取代基取代,
苯基任选被0至5个取代基取代,
喹啉基和异喹啉基萘基选任选被0至6个取代基取代,
萘基选任选被0至7个取代基取代,
以上的取代基选自:羟基,卤素,氰基,硝基,-COOH,羧酸酯基,取代或未经取代的氨基,硅基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R28选自氢,取代或者未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基。
本发明涉及通式化合物化合物(V),其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中包括通式化合物化合物(VIII),
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中:
R22,R23,R24,R25,R26独立地是氢,卤,-OH,-NR′R″,-NO2,-Si(R′)3,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,-S(O)mR′,-S(O)nNR′R″,-OS(O)nR′,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″,-S(O)nNH(C=O)NR′R″,-NR′S(O)nR″,-NR′S(O)nNR′R″,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基;
环Y,R1,R2,R3,R4,R5,R6,R7,R8,R′,R″,M,W,K,Z,m,n,p,q,s,t同前文所述。
本发明涉及通式化合物化合物(VIII),其中,R22,R23,R24,R25,R26独立地是-H,卤,-OH,-NO2,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,取代的或未经取代的氨基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基,还选自包括:
R27选自苯基,C1-6烷基,环(C3-8)烷基,噻吩基,呋喃基,咪唑基,吡啶基,嘧啶基,哒嗪基,喹啉基,异喹啉基,苯乙炔基,苯甲基,苯乙烯基,萘基,取代氨基,吗啉基,哌啶基,N-甲基哌嗪基,四氢吡咯基,六氢吡啶基,樟脑烷基,对甲苯基,
其中,C1-6烷基任选被0至13个取代基取代,
噻吩基,呋喃基和咪唑基任选被0至3个取代基取代,
吡啶基任选被0至4个取代基取代,
嘧啶基和哒嗪基任选被0至3个取代基取代,
苯基任选被0至5个取代基取代,
喹啉基和异喹啉基萘基选任选被0至6个取代基取代,
萘基选任选被0至7个取代基取代,
以上的取代基选自:羟基,卤素,氰基,硝基,-COOH,羧酸酯基,取代或未经取代的氨基,硅基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R28选自氢,取代或者未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基。
本发明涉及通式化合物化合物(V),其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中包括通式化合物化合物(IX),
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中:
R9,R10,R11,R12,R13,R14,R15,R16,R17,R18,R19,R20,R21同前文所述;
R22,R23,R24,R25,R26同前文所述;
R5,R6,R7,R8,K,Z,M,q同前文所述。
本发明涉及通式化合物化合物(IX),其中:
K为-C(O)-,-SO2-,-SO2NH-,-P(O)R5R6;
R17,R18,R19,R20,R21,R22,R23,R24,R25,R26独立地是-H,卤,-OH,-NO2,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,取代的或未经取代的氨基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基,还选自包括:
R27选自苯基,C1-6烷基,环(C3-8)烷基,噻吩基,呋喃基,咪唑基,吡啶基,嘧啶基,哒嗪基,喹啉基,异喹啉基,苯乙炔基,苯甲基,苯乙烯基,萘基,取代氨基,吗啉基,哌啶基,N-甲基哌嗪基,四氢吡咯基,六氢吡啶基,樟脑烷基,对甲苯基,
其中,C1-6烷基任选被0至13个取代基取代,
噻吩基,呋喃基和咪唑基任选被0至3个取代基取代,
吡啶基任选被0至4个取代基取代,
嘧啶基和哒嗪基任选被0至3个取代基取代,
苯基任选被0至5个取代基取代,
喹啉基和异喹啉基萘基选任选被0至6个取代基取代,
萘基选任选被0至7个取代基取代,
以上的取代基选自:羟基,卤素,氰基,硝基,-COOH,羧酸酯基,取代或未经取代的氨基,硅基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R28选自氢,取代或者未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基。
本发明涉及的化合物,该化合物选自以下化合物,但不局限于以下化合物范围:
或其药用可接受的盐。
本发明涉及通式(V)所示化合物,其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类的方法,其包括以下步骤:
以上的制备路线描述如下:X1和X2为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得,X1和X2在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物V。
本发明涉及通式(V)所示化合物,制备一种药物组合物,其包含任意一项的化合物和药学上可以接受的载体。
本发明涉及通式(V)所示化合物组成的一种药物组合物,所述组合物包括给予需要治疗的患者有效治疗量的任意一项的化合物。
本发明涉及通式(V)所示化合物中任意一项化合物在制备用于降低患者血浆和/或肝的脂类水平的药物中的用途。
本发明涉及通式(V)所示化合物中任意一项化合物在制备用于治疗高脂血症,高胆固醇血症,高甘油三酯血症,肝脂肪变性,代谢综合征,抗肿瘤药物中的用途。
本发明涉及通式(V)所示化合物中任意一项化合物在制备用于增加LDLR表达和/或降低PCSK9表达的药物中的用途。
本发明涉及通式(V)所示化合物,本发明公开的化合物具有以下有益效果:
1、本发明公开的具有通式(V)小分子化合物,在抑制PCSK9基因表达,增加细胞LDLR的表达,增强肝细胞对LDL的摄取能力中的显著作用,有望成为新一代降脂药。
PCSK9抑制剂作为降脂药物的开发是当今大型跨国制药公司努力研发新型心血管疾病药物的重要方向,期待这类药物超越他汀类成熟的降脂药物。大型制药公司正密锣紧鼓地推动PCSK9抑制剂药物开发工作,目前的研究工作主要集中在生物制品药物(包括蛋白药物和长链核酸药物)的开发,目前,还没有小分子PCSK9抑制剂成为临床候选药物。如下表:
生物制品药物与小分子药物针对治疗同一病症时,生物药具有成本高昂,只能采用注射制剂等有限的制剂方式等缺点,而小分子药物具有制造成本低廉,制剂方法多样等优点,本发明公开的有通式(V)小分子化合物,在细胞水平表现出显著的抑制PCSK9基因表达,增强肝细胞对LDL的摄取能力中的显著作用,有望成为具有新一代降脂药。另一方面,小分子药物的制剂方案比生物大分子药物选择面更加广泛,有利于后期药物开发多种剂型药物的开发,相比生物大分子药物而言,可以提供给为广泛的制剂类型,满足人们的需求。
2、与现有的专利文献公开的以PCSK9为作用的靶点的化合物相比,本发明公开的具有通式(V)化合物,结构新颖,具有崭新的结构特征,有望成为对PCSK9具有新颖作用机理的候选药物,并最终成为新一代具有新颖作用机制的降脂药物。
现有公开专利文献报道了几类作用于PCSK9靶点的小分子化合物,以专利申请人分类总结如下:
a、CVIPharmaceuticalLimited的申请专利WO2010075469,WO2011006000中报道了基于天然产物紫堇碱结构改造得到的小分子化合物,该类基于天然产物结构的小分子化合物,其制造工艺较为复杂,部分合成方法需要使用剧毒的化学试剂,会给操作工人和自然环境带来巨大的危害。
b、CadilaHealthcareLimited的申请专利WO2011051961,WO2012090220,WO2013132509,WO2014002105,WO2014002106中报道了几类小分子化合物,这几类小分子化合物在分子结构特点上主要含有一个共同的化学结构片段——六氢吡喃甲基氨基结构片段。该结构片段可能在化合物结构与生物活性中扮演着重要的角色。
c、KowaCompanyLimited申请专利WO2011152508,JP2013136572,WO2013137371,WO2014017569中报道了几类小分子化合物,这类小分子化合物分子结构相对复杂,一般的实施例化合物还含有三个手性中心,其制造难度相对较大,实施例化合物一般需要六步化学反应(不包括含有手性中心的结构片段的构建)才能制备得到目标化合物。
d、AmorchemHoldingsINC.申请专利WO2014139008中报道了一类小分子化合物,该类小分子化合物的部分实施例化合物主要结构特点在于含有“硼酸酯和硼酸”结构片段,尽管目前已经上市多发性骨髓瘤治疗药物——硼替佐米(含有“硼酸”结构片段),但是“硼酸类”药物在非肿瘤治疗领域(例如:糖尿病,高脂血症等等)的应用仍然受到限制,主要原因在于含硼药物的潜在的神经毒性副作用,以及其潜在的与生物机体“不可逆结合”的化学特性(Chem.Res.Toxicol.,2013,26(4),pp608–615),该化学特性的在药物分子设计中可能造成的潜在的“致癌性”,“生殖毒性”已经广泛受到药物化学家的重视。
e、ShifaBiomedicalCorporation申请专利WO2014150326,WO2014150395中报道了两类小分子化合物,这些小分子化合物的制备方法相对复杂,某些活性比较优秀的化合物的制备需要使用重金属催化反应,并且使用异氰酸酯化合物。
以上总结的就是目前公开的文献中以PCSK9为作用靶点的小分子化合物。本发明公开的化合物同样以PCSK9为作用靶点,该类化合物与上述总结的几类小分子化合物均可能成为未来基于PCSK9作用靶点的新型药物。
与现有的专利文献公开的以PCSK9为作用的靶点的化合物相比,本发明公开的具有通式(V)化合物,结构新颖,具有崭新的独特结构特征,预示着本发明公开的化合物其新颖的分子结构特点,有可能带来意想不到“类药性特点”,有望成为对PCSK9具有新颖作用机理的候选药物,并最终成为新一代具有新颖作用机制的降脂药物。
3、本发明公开的具有通式(V)化合物,具有原料易得,制备过程操作简单,成本低廉优势。
本发明公开的具有通式(V)的小分子化合物,主要采用市售中间体,然后采用简单的化学反应进行片段偶联反应制备得到。例如采用市售的具有“胺”,“酰卤”等官能团的起始物料,然后进行一步构建“酰胺键”化学反应或其它化学反应即可以制备得到目标化合物。因此,本发明公开的具有通式(V)化合物,具有原料易得,制备过程操作简单,成本低廉的优势。
4、本发明公开的具有通式(V)化合物具有活化AMPK激酶的活性,提示本发明化合物不但可以开发成为新一代降脂药,而且可以起到较好控制血糖的作用,为广大的代谢综合征患者在降脂和降糖方面获得综合的收益比现有单一作用药物更具优势。
本发明公开的通式化合物(V)制备主要参照以下的方案进行制备:
以上的制备路线描述如下:X1和X2为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。X1和X2在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物V。
现以本发明专利中具有代表性的合成制备流程为例,介绍通式化合物(V)制备方案,本发明化合物制备方案不局限于以下代表性流程:
方案1:当K=-C(O)-,-C(O)O-,-C(O)NH-时,
X1,X3,X3′,X3″为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,在一定的碱性试剂存在的条件下,通过偶联反应制备得到V-1,V-1′,V-1″。
方案2:当K=-SO2-,-SO2O-,-SO2NH-时,
X1,X4,X4′,X4″为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,在一定的碱性试剂存在的条件下,通过偶联反应制备得到V-2,V-2′,V-2″。
方案3:当K=-P(O)-时,
X1和X5为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,一定的碱性试剂存在的条件下,通过偶联反应制备得到V-3。
更进一步地,通式(VI):
W1和X2为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。W1和X2在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物VI。
更进一步地,通式(VII):
Y1和X2为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。Y1和X2在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物VII。
更进一步地,通式(VIII):
X1和Z1为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。X1和Z1在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物VIII。
更进一步地,通式(IX):
现以本发明专利中具有代表性的合成制备流程为例,介绍通式化合物(VIII)制备方案,本发明化合物制备方案不局限于以下代表性流程:
方案1:当K=-C(O)-,-C(O)O-,-C(O)NH-时,
Y1和Z2,Z2′,Z2″为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,在一定的碱性试剂存在的条件下,通过偶联反应制备得到IX-1,IX-1′,IX-1″。
方案2:当K=-SO2-,-SO2O-,-SO2NH-时,
Y1和Z3,Z3′,Z3″为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,在一定的碱性试剂存在的条件下,通过偶联反应制备得到IX-2,IX-2′,IX-2″。
方案3:当K=-P(O)-时,
Y1和Z4为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。将Y1和Z4在一定的反应条件下,一定的碱性试剂存在的条件下,通过偶联反应制备得到IX-3。
附图说明:
图1显示了化合物处理后,显微镜下观察到的荧光强度评价样品对肝细胞摄取LDL能力的影响。
图2显示了高脂SD大鼠,经本发明部分化合物口服灌胃给药四周后,血清中低密度脂蛋白胆固醇(LDL-C)的测定结果比较。
图3显示了高脂SD大鼠,经本发明部分化合物口服灌胃给药四周后,血清中总胆固醇(TC)的测定结果比较。
图4显示了高脂SD大鼠,经本发明部分化合物口服灌胃给药四周后,血清中谷丙转氨酶(ALT)的测定结果比较。
图5显示了高脂SD大鼠,经本发明部分化合物口服灌胃给药四周后,血清中谷草转氨酶(AST)的测定结果比较。
发明详述
在多个方面,本发明的技术提供了新颖的化合物,以及该化合物在降低血浆和/或肝的脂类水平的用途以及治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性、II型糖尿病、高血糖症、胰岛素抵抗症、肥胖症和代谢综合征中的用途。本文提供的化合物可被配制用于本文公开的方法中的药物组合物和药剂。本发明还提供了所述化合物用于制备药物配制物和药剂的用途,所述化合物在降低血浆和/或肝的脂类水平中的用途以及所述化合物在治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性、II型糖尿病、高血糖症,胰岛素抵抗症、肥胖症和代谢综合征中的用途。
下述术语在本文通篇中参照下述定义来使用。
通常,提到某个元素,例如氢或H,表示包括该元素的所有同位素。例如,如果R基团被定义为包括氢或H,其还包括氘和氚。包含放射性同位素(例如氚、C14、P32和S35)的化合物因此也在本发明的范围。用于将此类标记插入本发明的化合物中的手段是本领域技术人员基于本文公开的内容显而易见的。
通常,“经取代的”表示这样的如下文定义的有机基团(例如烷基),其中含有的一个或多个连接氢的键被连接非氢原子或非碳原子的键替换。经取代的基团还包括这样的基团:其中一个或多个连接碳原子或氢原子的键被一个或多个连接杂原子的键(包括双键或三键)替换。由此,除非另有指明,被取代的基团被一个或多个取代基取代。在一些实施方式中,取代基被1、2、3、4、5或6个取代基取代。取代基的例子包括卤(即,F,Cl,Br和I)、羟基、烷氧基、烯氧基、芳基氧基、芳烷基氧基、杂环基氧和杂环基烷氧基、羰基、羧基、酯、氨基甲酸盐/酯、肟、羟基胺、烷氧基胺、芳烷氧基胺、硫醇、硫化物、亚砜、砜、磺酰基、磺酰胺、胺、N-氧化物、肼、酰肼、腙、叠氮化物、酰胺、脲、脒、胍、烯胺、酰亚胺、异氰酸盐/酯、异硫代氰酸盐/酯、氰酸盐/酯、硫代氰酸盐/酯、亚胺、硝基、腈等等。
经取代的环基,例如经取代的环烷基、芳基、杂环基和杂芳基,还包括其中连接氢原子的键被连接碳原子的键替换的环和环系统。经取代的环烷基、芳基、杂环基和杂芳基还可被下文定义的经取代的或未经取代的烷基、烯基和炔基取代。
烷基包括包含1至20个碳原子的直链或支链基团,优选含有1至12个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基,及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基,非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的,当被取代时,取代基可以在任何可使用的连接点上被取代,所述取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、硫醇、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代、-C(O)R′、-C(O)OR′、-S(O)mR′、-NR′R″、-C(O)NR′R″、-NR′C(O)R″、-NR′S(O)mR″或-S(O)mNR′R″。
环烷基烷基是指饱和或部分不饱和单环或多环环状烃取代的烷基,环烷基环包含3至20个碳原子,优选包含3至12个碳原子,更优选包含3至10个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等;多环环烷基包括螺环、稠环和桥环的环烷基。
烯基指由至少由两个碳原子和至少一个碳-碳双键组成的如上定义的不饱和烷基,例如乙烯基、1-丙烯基、2-丙烯基、1-、2-或3-丁烯基等。烯基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、硫醇、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、-C(O)R′、-C(O)OR′、-S(O)mR′、-NR′R″、-C(O)NR′R″、-NR′C(O)R″、-NR′S(O)mR″或-S(O)mNR′R″。
环烯基指包括具有至少一个处于两个碳原子之间的双键的,如上文定义的不饱和环烷基。在一些实施方式中,环烯基可具有一个、两个或三个双键但是不包括芳香族化合物。环烯基包含4至14个碳原子,或在一些实施方式中,包含5至14个碳原子,优选包含5至10个碳原子,更优选包含5、6、7或8个碳原子。环烯基的例子包括环己烯基、环戊烯基、环己二烯基、丁二烯基、戊二烯基和己二烯基。
炔基指至少由两个碳原子和至少一个碳-碳三键组成的如上所定义的不饱和烷基,例如乙炔基、1-丙炔基、2-丙炔基、1-、2-或3-丁炔基等。炔基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、硫醇、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、-C(O)R′、-C(O)OR′、-S(O)mR′、-NR′R″、-C(O)NR′R″、-NR′C(O)R″、-NR′S(O)mR″或-S(O)mNR′R″。
芳基是不含杂原子的环状芳香烃。芳基在本文中包括单环、二环和三环系统。因此,芳基包括但不限于苯基、茂并芳庚基、二苯基、芴基、菲基、蒽基、茚基、茚满基、并环戊二烯基和萘基。在一些实施方式中,芳基在基团的环的部分中含有6-14个碳,优选6至12个,更优选6-10个碳原子。在一些实施方式中,芳基是苯基或萘基。虽然词组“芳基”包括含有稠合的环(例如稠合的芳香族-脂肪族环系统)的基团(例如茚满基、四氢萘基等等),但其不包括具有与环成员之一键合的其它基团(例如烷基或卤代基团)的芳基。甲苯基等基团被称为经取代的芳基。代表性的经取代的芳基可以是经单取代的或被取代超过一次的。例如,经单取代的芳基包括但不限于2-、3-、4-、5-或6-取代的苯基或萘基,其可被例如上文列出的取代基取代。
芳烷基是如上文定义的烷基,其中,烷基的氢或碳键被连接上文定义的芳基的键所替换。在一些实施方式中,芳烷基含有7至16个碳原子,优选7至14个碳原子,更优选7至10个碳原子。经取代的芳烷基可在烷基、芳基的部分被取代,或在烷基和芳基部分均被取代。代表性的芳烷基包括但不限于苄基和苯乙基和稠合的(环烷基芳基)烷基(例如4-茚满基乙基)。代表性的经取代的芳烷基可被例如上文列出的取代基取代一次或数次。
杂环基包括含有3个或多个环成员的芳香族(也被称为杂芳基)和非芳香族环状化合物,其中环成员中的一个或多个是杂原子,例如但不限于N、O和S。在一些实施方式中,杂环基含有1、2、3或4个杂原子。在一些例子中,杂环基包括具有3至16个环成员的单、二和三环。杂环基包括芳香族的、部分未饱和的和饱和的环系统,例如,咪唑基、咪唑啉基和咪唑烷基。词组“杂环基”包括稠合的环种类,这包括包含稠合的芳香族和非芳香族基团的那些,例如苯并三唑基、2,3-二氢苯并[1,4]二噁烷基和苯并[1,3]二氧杂环戊烯基。该词组还包括桥联的含有杂原子的多环系统,例如但不限于奎宁环基。但是,该词组不包括具有与环成员之一键合的其它基团(例如烷基、氧代或卤代基团)的杂环基。相反,这些被称为“经取代的杂环基”。杂环基包括但不限于吖丙啶基、吖丁啶基、吡咯烷基、咪唑烷基、吡唑烷基、噻唑烷基、四氢硫代苯基、四氢呋喃基、二氧杂环戊烯基、呋喃基、硫代苯基、吡咯基、吡咯啉基、咪唑基、咪唑啉基、吡唑基、吡唑啉基、三唑基、四唑基、噁唑基、异噁唑基、噻唑基、噻唑啉基、异噻唑基、噻重氮基、噁二唑基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、四氢吡喃基、四氢硫代吡喃基、氧硫杂环己烷、二氧六环基、二噻烷基、吡喃基、吡啶基、嘧啶基、哒嗪基、吡嗪基、三嗪基、二氢吡啶基、二氢二噻嗯基、二氢二硫酮基、高哌嗪基、奎宁环基、吲哚基、吲哚啉基、异吲哚基、氮杂吲哚基(吡咯并吡啶基)、吲唑基、吲哚嗪基、苯并三唑基、苯并咪唑基、苯并呋喃基、苯并硫代苯基、苯并噻唑基、苯并噁二唑基、苯并噁嗪基、苯并二噻嗯基、苯并噁噻嗯基、苯并噻嗪基、苯并噁唑基、苯并噻唑基、苯并噻重氮基、苯并[1,3]二氧杂环戊烯基、吡唑并吡啶基、咪唑并吡啶基(氮杂苯并咪唑基)、三唑并吡啶基、异噁唑并吡啶基、嘌呤基、黄嘌呤基、腺嘌呤基、鸟嘌呤基、喹啉基、异喹啉基、喹嗪基、喹喔啉基、喹唑啉基、酞嗪基、萘啶基、硫杂萘基、二氢苯并噻嗪基、二氢苯并呋喃基、二氢吲哚基、二氢苯并二噁烷基、四氢吲哚基、四氢吲唑基、四苯并咪唑基、四氢苯并三唑基、四氢吡咯并吡啶基、四氢吡唑并吡啶基、四氢咪唑并吡啶基、四氢三唑并吡啶基和四氢喹啉基。代表性的经取代的杂环基可经单取代或被取代超过一次,例如但不限于2-、3-、4-、5-或6-取代的或被例如上文列出的多种取代基二取代的吡啶基或吗啉基。
杂芳基是含有5个或更多个环成员原子的芳香族环化合物,其中一个或多个环成员是杂原子,例如但不限于N、O和S。杂芳基包括但不限于下述基团,例如,吡咯基、吡唑基、三唑基、四唑基、噁唑基、异噁唑基、噻唑基、吡啶基、哒嗪基、嘧啶基、吡嗪基、硫代苯基、苯并硫代苯基、呋喃基、苯并呋喃基、吲哚基、氮杂吲哚基(吡咯并吡啶基)、吲唑基、苯并咪唑基、咪唑并吡啶基(氮杂苯并咪唑基)、吡唑并吡啶基、三唑并吡啶基、苯并三唑基、苯并噁唑基、苯并噻唑基、苯并噻重氮基、咪唑并吡啶基、异噁唑并吡啶基、硫杂萘基、嘌呤基、黄嘌呤基、腺嘌呤基、鸟嘌呤基、喹啉基、异喹啉基、四氢喹啉基、喹喔啉基和喹唑啉基。杂芳基包括其中所有环都是芳香族的稠合环化合物,例如吲哚基,其还包括其中仅一个环是芳香族的稠合环化合物,例如2,3-二氢吲哚基。虽然词组“杂芳基”包括稠合的环化合物,但该词组不包括具有与环成员之一键合的其它基团(例如烷基)的杂芳基。相反,具有此类取代的杂芳基被称为“经取代的杂芳基”。代表性的经取代的杂芳基可被例如上文列出的多种取代基取代一次或数次。
杂环基烷基是如上文定义的烷基,但其中,烷基的氢或碳键被连接上文定义的杂环基的键所替换。经取代的杂环基烷基可在烷基、杂环基的部分被取代,或在烷基和杂环基部分均被取代。代表性的杂环基烷基包括但不限于吗啉-4-基-乙基、呋喃-2-基-甲基、咪唑-4-基-甲基、吡啶-3-基-甲基、四氢呋喃-2-基-乙基和吲哚-2-基-丙基。代表性的经取代的杂环基烷基可被例如上文列出的取代基取代一次或数次。
杂芳烷基是如上文定义的烷基,其中,烷基的氢或碳键被连接上文定义的杂芳基的键所替换。经取代的杂芳烷基可在烷基、杂芳基的部分被取代,或在烷基和杂芳基部分均被取代。代表性的经取代的杂芳烷基可被例如上文列出的取代基取代一次或数次。
本发明的化合物中,具有两个或多个连接点(即二价、三价或多价)的本文描述的基团被用前缀“亚”来命名。例如,二价烷基是亚烷基,二价芳基是亚芳基,二价杂芳基是杂亚芳基,等等。与本发明的化合物具有单个连接点的经取代的基团不使用“亚”命名。因此,例如,氯乙基在本文中不被称为氯亚乙基。
氧代基是指通过与氧原子相连构成的取代基团,其中与氧原子相连接的基团为经取代或者未经取代的烷基,芳基,杂芳基,环烷基,烷基酰基,芳基酰基,杂芳基酰基。以上的基团与氧原子连接即可以构成烷氧基,芳氧基,杂芳氧基,环烷基氧基,烷基酰氧基,芳基酰氧基,杂芳基酰氧基,环烷基酰氧基。
烷氧基是羟基(-OH)中连接氢原子的键被连接上文定义的经取代的或未经取代的烷基的碳原子的键替换的取代基。线性烷氧基的例子包括但不限于甲氧基、乙氧基、丙氧基、丁氧基、戊氧基、己氧基等等。带支链的烷氧基的例子包括但不限于异丙氧基、仲丁氧基、叔丁氧基、异戊氧基、异己氧基等等。环烷氧基的例子包括但不限于环丙基氧、环丁基氧、环戊基氧、环己基氧等等。代表性的经取代的烷氧基可被例如上文列出的取代基取代一次或数次。
术语“烷酰基”和“烷酰基氧”在本文中使用时分别指-C(O)-烷基和-O-C(O)-烷基,它们每个含有2-5个碳原子。
术语“芳基氧”和“芳基烷氧基”分别指经取代的或未经取代的芳基与氧原子键合构成的取代基,经取代的或未经取代的芳烷基与氧原子键合构成的取代基。例子包括但不限于苯氧基、萘基氧和苄氧基。代表性的经取代的芳基氧和芳基烷氧基可被例如上文列出的取代基取代一次或数次。
术语“羧酸”在本文中使用时指-COOH基团。
术语“羧酸酯”在本文中使用时指-COOR′基团。R′是如本文定义的经取代的或未经取代的烷基、环烷基、烯基、炔基、芳基、芳烷基、杂环基烷基或杂环基。
术语“酰胺”(或“酰胺基”)包括C-酰胺基团和N-酰胺基团,即分别是-C(O)NR′R″和-NR′C(O)R″基团。R′和R″独立地是如本文定义的氢或者经取代的或未经取代的烷基、烯基、炔基、环烷基、芳基、芳烷基、杂环基烷基或杂环基。酰胺基因此包括但不限于氨基甲酰基(-C(O)NH2)和甲酰胺基团(-NHC(O)H)。在一些实施方式中,酰胺是-NR′C(O)-(C1-5烷基),该基团被称为“羰基氨基”,在另一些实施方式中,酰胺是-NHC(O)-烷基,该基团被称为“烷酰基氨基”。
术语“腈”或“氰基”在本文中使用时指-CN基团。
氨基甲酸盐/酯包括N-氨基甲酸盐基团和O-氨基甲酸盐基团,即分别是-NR′C(O)OR″和-OC(O)NR′R″基团。R′和R″独立地是如本文定义的经取代的或未经取代的烷基、烯基、炔基、环烷基、芳基、芳烷基、杂环基烷基或杂环基。R′还可以是H。
术语“胺”(或“氨基”)在本文中使用时指-NR′R″基团,其中R′和R″独立地是如本文定义的氢或者经取代的或未经取代的烷基、烯基、炔基、环烷基、芳基、芳烷基、杂环基烷基或杂环基。在一些实施方式中,胺是烷基氨基、二烷基氨基、芳基氨基或烷基芳基氨基。在其它一些实施方式中,胺是NH2、甲基氨基、二甲基氨基、乙基氨基、二乙基氨基、丙基氨基、异丙基氨基、苯基氨基或苄基氨基。
术语“磺酰胺”包括S-磺酰胺基团和N-磺酰胺基团,即分别是-SO2NR′R″和-NR′SO2R″基团。R′和R″独立地是如本文定义的氢或者经取代的或未经取代的烷基、烯基、炔基、环烷基、芳基、芳烷基、杂环基烷基或杂环基。磺酰胺基团因此包括但不限于磺酰基(-SO2NH2)。在本文的一些实施方式中,磺酰胺是-NHSO2-烷基,其被称为“烷基磺酰基氨基”。
术语“硫醇”指-SH基团,而硫化物包括-SR′基团,亚砜包括-S(O)R′基团,砜包括-SO2R′基团,以及磺酰氧基包括-OSO2R′,磺酸氧基包括-OSO2OR′。R′独立地是如本文定义的经取代的或未经取代的烷基、环烷基、烯基、炔基、芳基芳烷基、杂环基或杂环基烷基。在一些实施方式中,硫化物是烷基硫醇基团,-S-烷基。
术语“脲”指-NR′-C(O)-NR′R″基团。R′和R″基团独立地是如本文定义的氢或者经取代的或未经取代的烷基、烯基、炔基、环烷基、芳基、芳烷基、杂环基或杂环基烷基。
术语“脒”指-C(NR′)NR′R″和-NR′C(NR′)R″,其中,R′和R″每个独立地是如本文定义的氢或者经取代的或未经取代的烷基、环烷基、烯基、炔基、芳基芳烷基、杂环基或杂环基烷基。
术语“胍”指-NR′C(NR′)NR′R″,其中R′和R″每个独立地是如本文定义的氢或者经取代的或未经取代的烷基、环烷基、烯基、炔基、芳基芳烷基、杂环基或杂环基烷基。
术语“烯胺”指-C(R′)=C(R′)NR′R″和-NR′C(R′)=C(R′)R″,其中R′和R″每个独立地是如本文定义的氢、经取代的或未经取代的烷基、环烷基、烯基、炔基、芳基芳烷基、杂环基或杂环基烷基。
术语“卤”或“卤代”在本文中使用时指溴、氯、氟或碘。在一些实施方式中,卤是氟。在其它一些实施方式中,卤是氯或溴。
术语“羟基”在本文中使用时可以指-OH或其离子化形式-O-。
术语“酰亚胺”指-C(O)NR′C(O)R″,其中R′和R″每个独立地是如本文定义的氢或者经取代的或未经取代的烷基、环烷基、烯基、炔基、芳基芳烷基、杂环基或杂环基烷基。
术语“含氮杂环基”指含有氮原子的环系,该环系可以“骈合”芳香和非芳香环系,或者通过“螺碳原子”链接其他环系,例如以下结构:
等等。
术语“亚胺”指-CR′(NR″)和-N(CR′R″)基团,其中R′和R″每个独立地是如本文定义的氢或经取代的或未经取代的烷基、环烷基、烯基、炔基、芳基芳烷基、杂环基或杂环基烷基、并且满足:R′和R″不同时是氢。
术语“硝基”在本文中使用时指-NO2。
术语“三氟甲基”在本文中使用时指-CF3。
术语“三氟甲氧基”在本文中使用时指-OCF3。
本文描述的化合物的可药用盐在本发明的范围内,其包括这样的酸加成盐或碱加成盐,所述盐保持了预期的药理学活性并且从生物学角度而言不是具有潜在不良效果的(例如盐没有过分的毒性、致敏性或刺激性,并且是生物可利用的)。当本发明的化合物具有碱性基团(例如,氨基)时,可与无机酸(例如盐酸、氢硼酸、硝酸、硫酸和磷酸)、有机酸(例如藻酸盐、甲酸、乙酸、苯甲酸、葡糖酸、延胡索酸、草酸、酒石酸、乳酸、马来酸、柠檬酸、琥珀酸、苹果酸、甲磺酸、苯磺酸、萘磺酸和对甲苯磺酸)或酸性氨基酸(例如天冬氨酸和谷氨酸)形成可药用盐。当本发明的化合物具有酸性基团,例如羧酸基团时,其可与金属,例如碱金属和碱土金属(例如Na+、Li+、K+、Ca2+、Mg2+、Zn2+)、氨或有机胺(例如二环己基胺、三甲基胺、三乙基胺、吡啶、乙醇胺、二乙醇胺、三乙醇胺)或碱性氨基酸(例如精氨酸、赖氨酸和鸟氨酸)形成盐。此类盐可在对化合物的分离和纯化期间“一锅法”制备,或者可通过将游离碱或游离酸经纯化后化合物分别与合适的酸或碱单独反应并且分离由此形成的盐来制备此类盐。
本领域技术人员已知的,本发明的化合物可展示出互变异构、构象异构、几何异构和/或立体异构的现象。虽然本说明书和权利要求中的式图仅代表可能的互变异构、构象异构、立体异构或几何异构形式之一,但是应当理解,本发明包括化合物的具有本文描述的一种或多种用途的任何互变异构、构象异构、立体异构和/或几何异构形式以及这些多种不同形式的混合物。
本领域技术人员易于理解的,大范围的官能团和其它结构可展示出互变异构体,本文描述的化合物的所有互变异构体都在本发明的范围内。
除非明确指示了立体化学,化合物的立体异构体,包括结构的所有手性、非对映异构和外消旋形式。因此,用于本发明中的化合物包括在任何或所有非对称原子处富集或拆分的光学异构体。外消旋和非对映异构混合物,以及各光学异构体,均可被分离或合成,以基本上不含其对应异构体或非对映异构体,这些立体异构体也在本发明的范围内。
本发明的化合物可作为溶剂化物存在,尤其是作为水合物。水合物可在化合物或包含化合物的组合物的制造期间形成,或者水合物可随着时间由于化合物的吸湿性质而形成。本发明的化合物还可作为有机溶剂化物存在,包括醚和醇溶剂化物等等。对任何特定的溶剂化物的鉴定和制备都是合成有机或药物化学领域普通技术人员已知的。
脂类包括合成的和天然存在的脂溶性化合物,其包括中性和两性分子。两性脂类典型地包含亲水组分和疏水组分。示例性脂类包括脂肪酸、甘油三酯、中性脂肪、磷脂、醣脂、脂肪醇、蜡、萜、类固醇(例如胆固醇)和表面活性剂。
“脂类降低试剂”在本文中使用时指施用给患者时具有一种或多种下述作用的化合物:增加LDLR的肝表达;增加LDLRmRNA在肝细胞中的半衰期;增加肝对血浆LDL、胆固醇或甘油三酯的摄取;增强肝的脂肪酸氧化,降低肝的甘油三酯合成和分泌,以及降低血浆和/或肝的总胆固醇、LDL-胆固醇、VLDL-胆固醇或甘油三酯水平。本文公开的脂类降低试剂包括本发明中的化合物。
在一个方面,本发明提供了利用本发明化合物制造在降低患者血浆和/或肝的脂类水平的药物中的用途,包括向所述患者施用脂类降低有效量的如本文所述的化合物或组合物。降低的脂类水平可以是总胆固醇、LDL-胆固醇(LDL-C)、甘油三酯(TG)和未酯化的长链脂肪酸中的一种或多种。
本文描述的化合物和组合物可用于预防或治疗下述疾病,包括例如,高脂血症,高胆固醇血症,高甘油三酯血症,脂肪肝(肝脂肪变性),II型糖尿病,高血糖症,肥胖症或胰岛素抵抗症和代谢综合征。治疗的方法包括向需要治疗的受试者施用治疗有效量的本文所述的化合物或组合物。本发明的化合物还可用于治疗或预防特征在于升高的血浆或肝胆固醇或甘油三酯或与升高的血浆或肝胆固醇或甘油三酯相关的疾病状态或病态。本发明的技术还提供使用本发明化合物制造治疗或预防疾病(例如,高脂血症、高胆固醇血症、高甘油三酯血症、脂肪肝、II型糖尿病,高血糖症,肥胖症或胰岛素抵抗症或代谢综合征)的有效量药物的用途。
本文公开的化合物和组合物通过增加LDLR的肝表达,通过增加LDLRmRNA的稳定性,通过增加LDLR基因转录,通过抑制前蛋白转化酶枯草杆菌蛋白酶/kexin9型(proproteinconvertasesubtilisin/kexintype9)(PCSK9)介导的LDLR蛋白的降解或上述可能的细胞机制的全部,来降低脂类水平。肝中增加的LDLR水平增加了血浆LDL-C的摄取和加工,从而导致胆固醇、LDL-C和甘油三酯的血浆水平降低。此外,化合物可通过活化AMP活化的蛋白激酶(AMPK)(生物能量代谢调节的关键分子)来增加乙酰CoA羧化酶(ACC)的磷酸化。ACC的增加的磷酸化增强了肝中的脂肪酸氧化,导致肝的TG积累降低,以及导致TG以VLDL形式分泌,这还有助于减少TG、LDL-C、总胆固醇和未酯化的长链脂肪酸的血浆水平,从而防止或治疗与高脂血症相关的疾病。另一方面,我们相信,遗传学和药理学研究表明,AMPK是机体保持葡萄糖平衡所必需的,化合物通过活化AMPK,最终起到治疗II型糖尿病,高血糖症,肥胖症或胰岛素抵抗症或代谢综合征。
在另一个方面,本发明提供的化合物具有增加LDLR表达的用途,包括向需要其的受试者施用治疗有效量的本文所述的化合物或组合物,由此增加所述受试者中的LDLR表达。在本发明的另一方面,本发明提供了一种利用本发明化合物减少血浆LDL-胆固醇和/或血浆甘油三酯的用途,包括向需要其的患者施用治疗有效量的本文所述的化合物或组合物,由此减少所述患者的血浆LDL-胆固醇。
在另一个方面,本发明提供了包括化合物及其组合物的脂类降低试剂。化合物和组合物可用于本文所述的降低脂类的方法和治疗中。在一种实施方式中,本发明提供了式V化合物,其立体异构体、其互变异构体、其溶剂化物和/或其可药用盐。
在另一个方面,本发明的技术提供了包含本文公开的任何化合物和可药用载体或一种或多种赋形剂或填料的药物组合物和药剂。在一些实施方式中,提供了治疗选自由高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性和代谢综合征构成的组的病况的药物组合物。此类组合物包括脂类降低有效量的本文所述的任何化合物。在一种实施方式中,将药物组合物包装成单位剂量形式。在施用给需要其的受试者时,单位剂量形式能有效降低血流和/或肝中的脂类水平(例如总胆固醇、LDL-胆固醇、甘油三酯和未酯化的长链脂肪酸中的至少一种)。
可通过将本发明的一种或多种化合物、其可药用盐、其立体异构体、其互变异构体或其溶剂化物与可药用载体、赋形剂、粘合剂、稀释剂等等混合,来制备药物组合物,以防止或治疗与增加的血浆和/或肝的脂类水平相关的病症。本文所述的化合物和组合物可用于制备防止或治疗与增加的血浆和/或肝脂类水平相关的多种病症(例如高脂血症、高胆固醇血症、肝脂肪变性和代谢综合征)的配制物和药剂。此类组合物可以是例如颗粒、粉末、片剂、胶囊、糖浆、栓剂、注射剂、乳液、酏剂、悬浮液或溶液的形式。本发明的组合物可被配制成用于多种施用途径的各种形式,例如,通过口服、肠胃外、局部、直肠、经鼻、阴道施用或者通过植入的贮器来施用。肠胃外或全身性施用包括但不限于皮下、静脉内、腹膜内和肌内、注射。下述剂量形式作为例子给出,其不应被解释为限制本发明的技术。
含活性成分的药物组合物可以是适用于口服的形式,例如片剂、糖锭剂、锭剂、水或油混悬液、可分散粉末或颗粒、乳液、硬或软胶囊,或糖浆剂或酏剂。可参照本领域任何已知制备药用组合物的方法制备口服组合物,此类组合物可含有一种或多种选自以下的成分:甜味剂、矫味剂、着色剂和防腐剂,以提供悦目和可口的药用制剂。片剂含有活性成分和用于混合的适宜制备片剂的无毒的可药用的赋形剂。这些赋形剂可以是惰性赋形剂,如碳酸钙、碳酸钠、乳糖、磷酸钙或磷酸钠;造粒剂和崩解剂,例如微晶纤维素、交联羧甲基纤维素钠、玉米淀粉或藻酸;粘合剂,例如淀粉、明胶、聚乙烯吡咯烷酮或阿拉伯胶和润滑剂,例如硬脂酸镁、硬脂酸或滑石粉。这些片剂可以不包衣或可通过掩盖药物的味道或在胃肠道中延迟崩解和吸收,因而在较长时间内提供缓释作用的已知技术将其包衣。例如,可使用水溶性味道掩蔽物质,例如羟丙基甲基纤维素或羟丙基纤维素,或延长时间物质例如乙基纤维素、醋酸丁酸纤维素。
也可用其中活性成分与惰性固体稀释剂例如碳酸钙、磷酸钙或高岭土混合的硬明胶胶囊,或其中活性成分与水溶性载体例如聚乙二醇或油溶媒例如花生油、液体石蜡或橄榄油混合软明胶胶囊提供口服制剂。
水悬浮液含有活性物质和用于混合的适宜制备水悬浮液的赋形剂。此类赋形剂是悬浮剂,例如羧基甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、藻酸钠、聚乙烯吡咯烷酮和阿拉伯胶;分散剂或湿润剂可以是天然产生的磷脂例如卵磷脂,或烯化氧与脂肪酸的缩合产物例如聚氧乙烯硬脂酸酯,或环氧乙烷与长链脂肪醇的缩合产物,例如十七碳亚乙基氧基鲸蜡醇,或环氧乙烷与由脂肪酸和己糖醇衍生的部分酯的缩合产物,例如聚环氧乙烷山梨醇单油酸酯,或环氧乙烷与由脂肪酸和己糖醇酐衍生的偏酯的缩合产物,例如聚环氧乙烷脱水山梨醇单油酸酯。水混悬液也可以含有一种或多种防腐剂例如尼泊金乙酯或尼泊金正丙酯、一种或多种着色剂、一种或多种娇味剂和一种或多种甜味剂,例如蔗糖、糖精或阿司帕坦。
油混悬液可通过使活性成分悬浮于植物油如花生油、橄榄油、芝麻油或椰子油,或矿物油例如液体石蜡中配制而成。油悬浮液可含有增稠剂,例如蜂蜡、硬石蜡或鲸蜡醇。可加入上述的甜味剂和娇味剂,以提供可口的制剂。可通过加入抗氧化剂例如丁羟茴醚或α-生育酚保存这些组合物。
通过加入水可使适用于制备水混悬也的可分散粉末和颗粒提供活性成分和用于混合的分散剂或湿润剂、悬浮剂或一种或多种防腐剂。适宜的分散剂或湿润剂和悬浮剂可说明上述的例子。也可加入其他赋形剂例如甜味剂、娇味剂和着色剂。通过加入抗氧化剂例如抗坏血酸保存这些组合物。
本发明的药物组合物也可以是水包油乳剂的形式。油相可以是植物油例如橄榄油或花生油,或矿物油例如液体石蜡或其混合物。适宜的乳化剂可以是天然产生的磷脂,例如大豆卵磷脂和由脂肪酸和己糖醇酐衍生的酯或偏酯例如山梨坦单油酸酯,和所述偏酯和环氧乙烷的缩合产物,例如聚环氧乙烷山梨醇单油酸酯。乳剂也可以含有甜味剂、娇味剂、防腐剂和抗氧剂。可用甜味剂例如甘油、丙二醇、山梨醇或蔗糖配制糖浆和酏剂。此类制剂也可含有缓和剂、防腐剂、着色剂和抗氧剂。
药物组合物可以是无菌注射水溶液形式。可在使用的可接受的溶媒和溶剂中有水、林格氏液和等渗氯化钠溶液。无菌注射制剂可以是其中活性成分溶于油相的无菌注射水包油微乳。例如将活性成分溶于大豆油和卵磷脂的混合物中。然后将油溶液加入水和甘油的混合物中处理形成微乳。可通过局部大量注射,将注射液或微乳注入患者的血流中。或者,最好按可保持本发明化合物恒定循环浓度的方式给予溶液和微乳。为保持这种恒定浓度,可使用连续静脉内递药装置。
药物组合物可以是用于肌内和皮下给药的无菌注射水或油混悬液的形式。可按已知技术,用上述那些适宜的分散剂或湿润剂和悬浮剂配制该混悬液。无菌注射制剂也可以是在无毒肠胃外可接受的稀释剂或溶剂中制备的无菌注射溶液或混悬液,例如1,3-丁二醇中制备的溶液。此外,可方便地用无菌固定油作为溶剂或悬浮介质。为此目的,可使用包括合成甘油单或二酯在内的任何调和固定油。此外,脂肪酸例如油酸也可以制备注射剂。
用于局部(包括经颊和舌下)或透皮施用本发明的化合物的剂量形式包括粉末、喷雾、油膏、糊剂、乳膏、洗液、凝胶、溶液和贴片。活性组分可在无菌条件下与可药用载体或赋形剂以及与可能需要的任何防腐剂或缓冲剂混合。粉末和喷雾可例如用赋形剂(例如糖、云母、硅酸、氢氧化钠、硅酸钙和聚胺粉末或这些物质的混合物)来制备。油膏、糊剂、乳膏和凝胶还可含有下述赋形剂,例如,动物和植物脂肪、油、蜡、石蜡、淀粉、黄芪胶、纤维素衍生物、聚乙二醇、硅酮、斑脱土、硅酸、云母和氧化锌或其混合物。还可使用吸收增强剂,来增加本发明的化合物穿透皮肤的流动。可通过提供速率控制膜(例如作为透皮贴片的一部分)或将化合物分散于聚合物基质或凝胶中来控制此类流动的速率。
可按用于直肠给药的栓剂形式给予本发明化合物。可通过将药物与在普通温度下为固体但在直肠中为液体,因而在直肠中会溶化而释放药物的适宜的无刺激性赋形剂混合来制备这些药物组合物。此类物质包括可可脂、甘油明胶、氢化植物油、各种分子量的聚乙二醇和聚乙二醇的脂肪酸酯的混合物。
本发明的化合物还可与可用于治疗或预防高脂血性疾病的其它传统治疗剂一起施用。用于与本发明的一种或多种化合物的组合疗法的示例性治疗试剂包括但不限于抗炎性药、治疗性抗体和胆固醇降低药,例如,他汀。可用于组合配制物和协作治疗的有用的附加治疗试剂包括,例如,抗高脂血症试剂;抗血脂异常试剂;抗糖尿病试剂,包括但不限于胆固醇生物合成抑制剂,例如HMG-CoA还原酶抑制剂(也被称为他汀,洛伐他汀,辛伐他汀,普伐他汀,氟伐他汀,瑞舒伐他汀,匹伐他汀和阿托伐他汀);HMG-CoA还原合酶抑制剂;角鲨烯环氧酶抑制剂或角鲨烯合成酶抑制剂(还被称为角鲨烯合酶抑制剂);微粒体甘油三酯转移蛋白(MTP)抑制剂;胆酸螯合剂阴离子交换树脂,包括但不限于消胆胺,降胆宁,考来维仑或经交联葡聚糖的二烷基氨基烷基衍生物;LDL受体诱导剂;贝特类,包括但不限于安妥明,苯扎贝特,非诺贝特和吉非贝齐;二甲双胍,罗格列酮,血浆HDL-升高试剂,包括但不限于烟酸,贝特类;抗高胆固醇血症试剂,包括但不限于胆固醇-摄取抑制剂;酰基辅酶A胆固醇酰基转移酶(ACAT)抑制剂,包括但不限于美林那胺;普罗布考;烟酸及其盐;烟酰胺;胆固醇吸收抑制剂,包括但不限于β-谷甾醇或依替米贝;维生素B6(吡哆醇)及其可药用盐,例如HCl盐;维生素B12(氰钴胺);维生素B3(烟酸和烟酰胺);抗氧化剂维生素,包括但不限于维生素C和维生素E和β胡萝卜素;β阻断剂;血管紧张素II受体(AT1)拮抗剂;血管紧张素转化酶抑制剂,肾素抑制剂;血小板聚集抑制剂,包括但不限于纤维蛋白原受体拮抗剂,即,糖蛋白IIb/IIIa纤维蛋白原受体拮抗剂;激素,包括但不限于雌激素;胰岛素;离子交换树脂;Ω-3油;苯氟雷司;廿六碳五烯酸乙酯和氨氯地平。附加疗法还可包括增加锻炼、手术和改变膳食(例如变为低胆固醇膳食)一些植物药品也可有效用于组合配制物和协作疗法,以治疗高脂血症,例如姜黄素,香胶甾酮,大蒜,大豆,可溶纤维,鱼油,绿茶,肉毒碱,铬,辅酶Q10,葡萄籽提取物,二聚泛酸,红曲米和蜂王浆。
小檗碱和相关化合物也可作为第二治疗试剂,与本发明的脂类降低试剂一起使用。例如,可使用硫酸小檗碱、盐酸小檗碱、氯化小檗碱、氧小檗碱、二氢小檗碱、8-氰基二氢小檗碱、四氢小檗碱N-氧化物、四氢小檗碱、原小檗碱、9-乙氧基羰基小檗碱、9-N,N-二甲基氨基甲酰基小檗碱和12-溴代小檗碱、小檗碱叠氮化物和小檗碱甜菜碱。
还可修饰本发明的化合物,例如通过共价联接有机结构片段或缀合物来进行,以改善药代动力学性质、毒性或生物利用性(例如增加的体内半衰期)。缀合物可以是线性的或带支链的亲水性聚合基团、脂肪酸基团或脂肪酸酯基团。聚合基团可包含可被本领域技术人员调节的分子量,以改善,例如药代动力学性质、毒性或生物利用性。示例性的缀合物可包括聚烷醇(例如聚乙二醇(PEG)、聚丙二醇(PPG)),碳水化合物聚合物,氨基酸聚合物或聚乙烯吡咯烷酮和脂肪酸或脂肪酸酯基团,它们每个均可独立包含大约8至大约70个碳原子。用于与本发明的化合物一起使用的缀合物还可用作为接头,例如用于任何合适的取代基或基团、放射性标记(标志物或标签)、卤、蛋白、酶、多肽、其它治疗试剂(例如药物或药品)、核苷、染料、寡核苷酸、脂类、磷脂和/或脂质体。在一个方面,缀合物可包括聚乙烯胺(PEI)、多聚甘氨酸、PEI和多聚甘氨酸的杂交体、聚乙二醇(PEG)或甲氧基聚乙二醇(mPEG)。缀合物还可将本发明的化合物连接至,例如,标记(发荧光的或发光的)或标志物(放射性素、放射性同位素和/或同位素),以包含本发明的探针。与本发明的化合物一起使用的缀合物在一个方面可改善体内半衰期。
术语“连结”和/或“结合”可表示化学或物理相互作用,例如本发明的化合物和感兴趣的目标之间的。连结或相互作用的例子包括共价键、离子键、亲水-疏水相互作用、疏水-疏水相互作用和复合体。“连结”一般还可称作“结合”或“亲和性”,它们每个均可用于描述多种化学或物理相互作用。测量结合或亲和性也是本领域技术人员的常规技术。
本文提供下面的实施例来阐述本发明的优点,以及进一步协助本领域普通技术人员制备或使用本发明的化合物或其盐、药物组合物、衍生物、代谢产物、前药、外消旋混合物或互变异构形式。本文的实施例还用于阐述本发明优选方面。实施例不应以任何方式被解释为限制由所附权利要求定义的本发明的范围。
具体实施方式
以下进一步解释本发明的一般方法,本发明的化合物可以通过本领域中公知的方法来制备,下面以本发明的优选化合物的制备方法为例详细进行说明但本发明化合物的制备方法不局限于此。
本发明公开的通式化合物(V)制备主要参照以下的方案进行制备:
以上的制备路线描述如下:X1和X2为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。X1和X2在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物V。
现以本发明专利中具有代表性的合成制备流程为例,介绍通式化合物(V)制备方案,本发明化合物制备方案不局限于以下代表性流程:
方案1:当K=-C(O)-,-C(O)O-,-C(O)NH-时,
X1,X3,X3′,X3″为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,在一定的碱性试剂存在的条件下,通过偶联反应制备得到V-1,V-1′,V-1″。
方案2:当K=-SO2-,-SO2O-,-SO2NH-时,
X1,X4,X4′,X4″为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,在一定的碱性试剂存在的条件下,通过偶联反应制备得到V-2,V-2′,V-2″。
方案3:当K=-P(O)-时,
X1和X5为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,一定的碱性试剂存在的条件下,通过偶联反应制备得到V-3。
更进一步地,通式(VI):
W1和X2为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。W1和X2在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物VI。
更进一步地,通式(VII):
Y1和X2为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。Y1和X2在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物VII。
更进一步地,通式(VIII):
X1和Z1为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。X1和Z1在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物VIII。
更进一步地,通式(IX):
现以本发明专利中具有代表性的合成制备流程为例,介绍通式化合物(VIII)制备方案,本发明化合物制备方案不局限于以下代表性流程:
方案1:当K=-C(O)-,-C(O)O-,-C(O)NH-时,
Y1和Z2,Z2′,Z2″为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,在一定的碱性试剂存在的条件下,通过偶联反应制备得到IX-1,IX-1′,IX-1″。
方案2:当K=-SO2-,-SO2O-,-SO2NH-时,
Y1和Z3,Z3′,Z3″为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。起始物料在一定的反应条件下,在一定的碱性试剂存在的条件下,通过偶联反应制备得到IX-2,IX-2′,IX-2″。
方案3:当K=-P(O)-时,
Y1和Z4为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得。将Y1和Z4在一定的反应条件下,一定的碱性试剂存在的条件下,通过偶联反应制备得到IX-3。
下面通过具体的实施例来进一步说明本发明,但本领域技术人员应知,本发明并不仅限于这些实施例。
化合物的结构是通过核磁共振(NMR)或质谱(MS)确定的。NMR的测定是用BrukerAVANCE-400核磁仪,测定溶剂为氘代二甲基亚砜(DMSO-d6),氘代氯仿(CDCl3),氘代甲醇(CD3OD),内标为四甲基硅烷(TMS),化学位移是以10-6(ppm)作为单位给出。
MS的测定用FINNIGANLCQAd(ESI)质谱仪(生产商:Thremo型号:FinniganLCQadvantageMAX)
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板,薄层色谱法(TLC)使用的硅胶板的规格是0.15mm~0.2mm,薄层层析分离纯化产品采用的规格是0.4mm~0.5mm硅胶板。
柱层析一般使用烟台黄海200~300目硅胶为载体。
本发明的已知的起始原料可以采用或参照本领域已知的方法来合成,或可购买自GmbH&Co.KG,AcrosOrgannics,AldrichChemicalCompany,TCIChemicals,安耐吉化学等公司。
实施例中如无特殊说明,反应均在氩气氛或氮气氛下进行。
氩气氛或氮气氛是指反应瓶连接一个约1L容积的氩气球或氮气球。
氢气氛是指反应瓶连接一个约1L容积的氢气球。
氢化反应常抽真空,充入氢气,反复操作3次。
实施例中如无特殊说明,反应的温度为室温,温度范围是20℃~30℃
实施例中的反应进程的监测采用薄层色谱法(TLC),反应所使用的展开剂的体系有:A:二氯甲烷和甲醇体系,B:正己烷和乙酸乙酯体系,C:正己烷和丙酮体系,D:正己烷,E:乙酸乙酯,溶剂的体积比根据化合物的极性不同而进行调节,也可以加入少量的三乙胺和酸性或碱性试剂等进行调节。
纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂的体系包括:A:二氯甲烷和甲醇体系,B:正己烷和乙酸乙酯体系,C:正己烷和丙酮体系,D:正己烷,E:乙酸乙酯,溶剂的体积比根据化合物的极性不同而进行调节,也可以加入少量的三乙胺和酸性或碱性试剂等进行调节。
实施例1
向25ml圆底烧瓶中加入1A(332mg,1mmol)和二氯甲烷,搅拌溶解后加入2B(229mg,1.2mmol)和三乙胺(180μl,1.3mmol),搅拌过夜,TLC检测反应完全,水洗,水层再用乙酸乙酯萃取两次,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,浓缩后经硅胶柱层析得到产物化合物1(412mg,90%)。1HNMR(400MHz,CDCl3)δ7.68(dd,J=8.1,4.1Hz,4H),7.40–7.28(m,4H),6.79(dd,J=46.0,9.1Hz,4H),3.17(ddd,J=9.4,6.8,4.0Hz,8H),2.45(s,6H);MS(ESI)m/z[M+H]+:486.98。
实施例2
向25ml圆底烧瓶中加入2A(332mg,1mmol)和二氯甲烷,搅拌溶解后加入2B(140μl,1.2mmol)和三乙胺(180μl,1.3mmol),搅拌过夜,TLC检测反应完全,水洗,水层再用乙酸乙酯萃取两次,合并有机相,依次用饱和食盐水洗涤,无水硫酸钠干燥,浓缩后经硅胶柱层析得到产物化合物2(331mg,92%)。1HNMR(400MHz,CDCl3)δ7.70(dd,J=8.3,1.7Hz,2H),7.43(d,J=1.0Hz,5H),7.31(d,J=7.8Hz,2H),6.92–6.83(m,2H),6.82–6.74(m,2H),3.45(dd,J=238.2,77.4Hz,8H),2.45(s,3H);MS(ESI)m/z[M+H]+:375.22。
实施例3
50ml圆底烧瓶中加入3A(583mg,3.0mmol),二氯甲烷(10ml)溶解,再加入加入草酰氯(426μl,5.0mmol)以及N,N-二甲基甲酰胺(1滴),室温下反应过夜。蒸干溶剂和过量的草酰氯,得到粗品3B。
50ml圆底烧瓶中加入3C(665mg,2.0mmol),二氯甲烷(10ml)溶解,再加入三乙胺(421μl,3.0mmol)。将粗品3B用二氯甲烷(5ml)溶解,缓慢滴加,室温反应过夜,TLC检测原料反应完全。浓缩后经硅胶柱层析(二氯甲烷:甲醇=100:1)分离得化合物3(500mg,产率49.2%)。1HNMR(400MHz,CDCl3)δ7.72(d,J=8.3Hz,2H),7.32(d,J=8.1Hz,2H),7.12(d,J=8.6Hz,2H),6.92–6.82(m,4H),6.82–6.75(m,2H),3.81(s,3H),3.77–3.75(m,2H),3.55–3.53(m,2H),3.12–3.09(m,4H),2.65(t,J=7.4Hz,2H),2.47(s,3H),2.38–2.34(m,2H),2.02–1.94(m,2H);MS(ESI)m/z[M+Na]+:531.04。
实施例4
化合物4为合成zzj-8-20B的副产物,可能是因为原料A10为三氟乙酸盐。
向25ml圆底烧瓶中加入4A(332mg,1mmol)和二氯甲烷,搅拌溶解后加入三氟乙酸酐(100μl)和三乙胺(180μl,1.3mmol),搅拌过夜,TLC检测反应完全,水洗,水层再用乙酸乙酯萃取两次,合并有机相,依次用饱和食盐水洗涤,无水硫酸钠干燥,浓缩后经硅胶柱层析得到产物化合物4(158mg,36.9%)。1HNMR(400MHz,CDCl3)δ7.73–7.67(m,2H),7.34–7.28(m,2H),6.92–6.85(m,2H),6.83–6.75(m,2H),3.86–3.79(m,2H),3.79–3.71(m,2H),3.23–3.14(m,4H),2.45(s,3H);MS(ESI)m/z[M+Na]+:450.92。
实施例5
50mL圆底烧瓶中加入化合物5A(200mg,0.602mmol),溶于二氯甲烷(10mL),再加入化合物5B(126μL,0.662mmol),三乙胺(101μL,0.722mmol),室温下搅拌过夜。反应液旋干,残渣中加入饱和碳酸氢钠水溶液,乙酸乙酯萃取,合并有机相,水洗涤,无水硫酸钠干燥,旋干后得到的残渣经柱层析(二氯甲烷:甲醇100:1)分离纯化得到无色膏状物化合物5(74mg,产率23.1%)。1HNMR(400MHz,CDCl3)δ7.93–7.84(m,4H),7.71–7.65(m,2H),7.56–7.43(m,6H),7.32–7.27(m,2H),6.87–6.80(m,2H),6.78–6.71(m,2H),3.26–3.17(m,4H),3.17–3.10(m,4H),2.44(s,3H);MS(ESI)m/z[M+H]+:533.00。
实施例6
50mL圆底烧瓶中加入6A(107mg,0.547mmol),草酰氯(116μL,1.37mmol),二氯甲烷(10mL),1滴DMF,室温下反应2h,旋干,得到6B,再依次加入6C(200mg,0.602mmol),二氯甲烷(20mL),TEA(114μL,0.820mmol),室温下搅拌过夜,反应液旋干,残渣中加入饱和碳酸氢钠水溶液,乙酸乙酯萃取,合并有机相,水洗涤,无水硫酸钠干燥,旋干后得到的残渣经柱层析(二氯甲烷:甲醇100:1)分离纯化得到无色膏状物化合物6(103mg,产率33.5%)。1HNMR(400MHz,CDCl3)δ7.72–7.66(m,2H),7.33–7.27(m,2H),6.88–6.78(m,4H),6.78–6.69(m,3H),3.86(s,6H),3.80–3.73(m,2H),3.71(s,2H),3.62–3.56(m,2H),3.11–3.04(m,2H),2.97–2.89(m,2H),2.44(s,3H);MS(ESI)m/z[M+Na]+:532.97。
实施例7
50mL圆底烧瓶中加入7A(87mg,0.501mmol),二氯亚砜(1.5mL),二氯甲烷(7mL),1滴DMF,在35℃油浴中反应4h,旋干,得到7B,再依次加入7C(200mg,0.602mmol),二氯甲烷(12mL),TEA(105μL,0.752mmol),室温下搅拌过夜,反应液旋干,残渣中加入饱和碳酸氢钠水溶液,乙酸乙酯萃取,合并有机相,水洗涤,无水硫酸钠干燥,旋干后得到的残渣经柱层析(二氯甲烷:甲醇100:1)分离纯化得到类白色固体化合物7(108mg,产率44.2%)。1HNMR(400MHz,DMSO-d6)δ9.34(s,1H),8.23–8.18(m,1H),8.13(s,1H),8.11–8.05(m,1H),7.92–7.82(m,1H),7.82–7.75(m,1H),7.74–7.67(m,2H),7.50–7.42(m,2H),6.94–6.87(m,2H),6.86–6.80(m,2H),3.85–3.75(m,2H),3.64–3.55(m,2H),3.29–3.20(m,2H),3.16–3.06(m,2H),2.41(s,3H);MS(ESI)m/z[M+Na]+:510.07。
实施例8
50mL圆底烧瓶中加入8A(132mg,0.602mmol),二氯亚砜(3mL),二氯甲烷(1mL),在60℃油浴中反应4h,旋干,得到8B,再依次加入8C(200mg,0.602mmol),二氯甲烷(12mL),TEA(126μL,0.903mmol),室温下搅拌过夜,反应液旋干,残渣中加入饱和碳酸氢钠水溶液,乙酸乙酯萃取,合并有机相,水洗涤,无水硫酸钠干燥,旋干后得到的残渣经柱层析(二氯甲烷:甲醇100:1)分离纯化得到白色固体化合物8(197mg,产率61.3%)。1HNMR(400MHz,CDCl3)δ7.72–7.66(m,2H),7.35(dd,J=8.2,2.4Hz,1H),7.32–7.24(m,3H),7.11(td,J=8.2,2.4Hz,1H),6.90–6.83(m,2H),6.81–6.74(m,2H),4.05–3.94(m,1H),3.93–3.82(m,1H),3.47–3.28(m,2H),3.28–3.11(m,3H),3.09–2.98(m,1H),2.44(s,3H);MS(ESI)m/z[M+Na]+:554.74。
实施例9
向25ml圆底烧瓶中加入9A(332mg,1mmol)和甲酸乙酯(10mL),室温搅拌过夜,TLC检测反应完全,水洗,水层再用乙酸乙酯萃取两次,合并有机相,依次用饱和食盐水洗涤,无水硫酸钠干燥,浓缩后经硅胶柱层析得到产物化合物9(108mg,27.8%)。1HNMR(400MHz,CDCl3)δ8.10(s,1H),7.73–7.67(m,2H),7.35–7.28(m,2H),6.91–6.85(m,2H),6.84–6.76(m,2H),3.74–3.64(m,2H),3.56–3.47(m,2H),3.20–3.05(m,4H),2.45(s,3H);MS(ESI)m/z[M+H]+:361.12。
实施例10
50mL圆底烧瓶中加入10A(62mg,0.501mmol),二氯亚砜(1.5mL),二氯甲烷(7mL),1滴DMF,在35℃油浴中反应4h,旋干,得到10B,再依次加入10C(200mg,0.602mmol),二氯甲烷(12mL),TEA(105μL,0.752mmol),室温下搅拌过夜,反应液旋干,残渣中加入饱和碳酸氢钠水溶液,乙酸乙酯萃取,合并有机相,水洗涤,无水硫酸钠干燥,旋干后得到的残渣经柱层析(二氯甲烷:甲醇100:1)分离纯化得到类白色固体化合物10(75mg,产率34.2%)。1HNMR(400MHz,CDCl3)δ8.62–8.56(m,1H),7.82(td,J=7.7,1.1Hz,1H),7.72–7.65(m,3H),7.36(dd,J=7.2,5.1Hz,1H),7.33–7.27(m,2H),6.89–6.82(m,2H),6.82–6.74(m,2H),3.99–3.89(m,2H),3.83–3.71(m,2H),3.29–3.20(m,2H),3.20–3.08(m,2H),2.44(s,3H);MS(ESI)m/z[M+H]+:460.20。
实施例11
50mL圆底烧瓶中加入11A(125mg,0.991mmol),草酰氯(211μL,2.48mmol),二氯甲烷(6mL),1滴DMF,在35℃油浴中反应4h,旋干,得到11B,再依次加入11C(428mg,1.29mmol),二氯甲烷(10mL),TEA(138μL,0.991mmol),室温下搅拌过夜,反应液旋干,残渣中加入饱和碳酸氢钠水溶液,乙酸乙酯萃取,合并有机相,水洗涤,无水硫酸钠干燥,旋干后得到的残渣经柱层析(二氯甲烷:甲醇100:1)分离纯化得到白色固体11(110mg,产率25.2%)。1HNMR(400MHz,DMSO-d6)δ7.78–7.64(m,2H),7.58–7.40(m,3H),7.04(s,1H),6.97–6.78(m,5H),5.05(s,2H),3.65–3.51(m,4H),3.25–3.04(m,4H),2.41(s,3H);MS(ESI)m/z[M+H]+:441.05。
实施例12
50mL圆底烧瓶中加入12A(235mg,1.35mmol),二氯甲烷(6mL),TEA(566μL,4.06mmol),搅拌溶解,再加入EDCI(259mg,1.35mmol),HOAT(184mg,1.35mmol),室温搅拌2h,再加入12B(300mg,0.902mmol),室温反应过夜。反应液旋干,残渣中加入水,乙酸乙酯萃取,合并有机相,水洗涤,无水硫酸钠干燥,旋干后得到的残渣经柱层析(二氯甲烷:甲醇100:1)分离纯化得到白色固体12(127mg,产率31.2%)。1HNMR(400MHz,CDCl3)δ8.54–8.47(m,2H),7.72–7.66(m,2H),7.66–7.61(m,1H),7.33–7.24(m,3H),6.89–6.82(m,2H),6.79–6.69(m,2H),3.83–3.69(m,4H),3.68–3.56(m,2H),3.15–2.96(m,4H),2.44(s,3H);MS(ESI)m/z[M+H]+:452.04。
实施例13
50mL圆底烧瓶中加入化合物13A(200mg,0.602mmol),用DMF(6mL)溶解,置于冰浴中,搅拌5min,加入氢化钠(22mg,0.903mmol),继续在冰浴中搅拌10min,升至室温搅拌30min,加入化合物13B(133mg,0.782mmol),室温下搅拌过夜。反应液中加入水和乙酸乙酯,萃取分层,合并有机相,水洗涤,无水硫酸钠干燥,旋干后得到的残渣经柱层析(二氯甲烷:甲醇100:1)分离纯化得到白色固体化合物13(52mg,产率18.5%)。1HNMR(400MHz,CDCl3)δ7.71–7.65(m,2H),7.33–7.27(m,2H),6.88–6.81(m,2H),6.80–6.72(m,2H),3.27–3.18(m,4H),3.11–3.03(m,4H),2.68(s,6H),2.66(s,6H),2.44(s,3H);MS(ESI)m/z[M+H]+:467.15。
实施例14
参照实施例3的实验方案和相关文献制备得到化合物14,MS(ESI)m/z[M+H]+,515.15。
实施例15
参照实施例3的实验方案和相关文献制备得到化合物15,MS(ESI)m/z[M+H]+:506.15。
实施例16
参照实施例3的实验方案和相关文献制备得到化合物16,MS(ESI)m/z[M+H]+:533.42。
实施例17
参照实施例3的实验方案和相关文献制备得到化合物17,MS(ESI)m/z[M+H]+:522.60。
实施例18
参照实施例3的实验方案和相关文献制备得到化合物18,MS(ESI)m/z[M+H]+:554.21。
实施例19
参照实施例3的实验方案和相关文献制备得到化合物19,MS(ESI)m/z[M+H]+:511.15。
实施例20
参照实施例3的实验方案和相关文献制备得到化合物20,MS(ESI)m/z[M+H]+:523.61。
实施例21
参照实施例3的实验方案和相关文献制备得到化合物21,MS(ESI)m/z[M+H]+:587.53。
实施例22
参照实施例3的实验方案和相关文献制备得到化合物22,MS(ESI)m/z[M+H]+:590.70。
实施例23
参照实施例3的实验方案和相关文献制备得到化合物23,MS(ESI)m/z[M+H]+:487.54。
实施例24
参照实施例3的实验方案和相关文献制备得到化合物24,MS(ESI)m/z[M+H]+:503.60。
实施例25
参照实施例3的实验方案和相关文献制备得到化合物25,MS(ESI)m/z[M+H]+:574.66。
实施例26
参照实施例3的实验方案和相关文献制备得到化合物26,MS(ESI)m/z[M+H]+:574.23。
实施例27
参照实施例3的实验方案和相关文献制备得到化合物27,MS(ESI)m/z[M+H]+:503.62。
实施例28
参照实施例3的实验方案和相关文献制备得到化合物28,MS(ESI)m/z[M+H]+:461.54。
实施例29
参照实施例3的实验方案和相关文献制备得到化合物29,MS(ESI)m/z[M+H]+:464.55。
实施例30
参照实施例3的实验方案和相关文献制备得到化合物30,MS(ESI)m/z[M+H]+:581.57。
实施例31
参照实施例3的实验方案和相关文献制备得到化合物31,MS(ESI)m/z[M+H]+:481.58。
实施例32
参照实施例3的实验方案和相关文献制备得到化合物32,MS(ESI)m/z[M+H]+:481.15。
实施例33
参照实施例3的实验方案和相关文献制备得到化合物33,MS(ESI)m/z[M+H]+:439.50。
实施例34
参照实施例3的实验方案和相关文献制备得到化合物34,MS(ESI)m/z[M+H]+:510.62。
实施例35
参照实施例3的实验方案和相关文献制备得到化合物35,MS(ESI)m/z[M+H]+:538.67。
实施例36
参照实施例3的实验方案和相关文献制备得到化合物36,MS(ESI)m/z[M+H]+:510.62。
实施例37
参照实施例3的实验方案和相关文献制备得到化合物37,MS(ESI)m/z[M+H]+:525.63。
实施例38
参照实施例3的实验方案和相关文献制备得到化合物38,MS(ESI)m/z[M+H]+:427.60。
实施例39
参照实施例3的实验方案和相关文献制备得到化合物39,MS(ESI)m/z[M+H]+:552.70。
实施例40
参照实施例3的实验方案和相关文献制备得到化合物40,MS(ESI)m/z[M+H]+:495.60。
实施例41
参照实施例3的实验方案和相关文献制备得到化合物41,MS(ESI)m/z[M+H]+:509.23。
实施例42
参照实施例3的实验方案和相关文献制备得到化合物42,MS(ESI)m/z[M+H]+:496.45。
实施例43
参照实施例3的实验方案和相关文献制备得到化合物43,MS(ESI)m/z[M+H]+:523.43。
实施例44
参照实施例3的实验方案和相关文献制备得到化合物44,MS(ESI)m/z[M+H]+:537.46。
实施例45
参照实施例3的实验方案和相关文献制备得到化合物45,MS(ESI)m/z[M+H]+:511.42。
实施例46
参照实施例3的实验方案和相关文献制备得到化合物46,MS(ESI)m/z[M+H]+:511.45。
实施例47
参照实施例3的实验方案和相关文献制备得到化合物47,MS(ESI)m/z[M+H]+:511.34。
实施例48
参照实施例3的实验方案和相关文献制备得到化合物48,MS(ESI)m/z[M+H]+:511.23。
实施例49
参照实施例3的实验方案和相关文献制备得到化合物49,MS(ESI)m/z[M+H]+:483.45。
实施例50
参照实施例3的实验方案和相关文献制备得到化合物50,MS(ESI)m/z[M+H]+:482.34。
实施例51
参照实施例3的实验方案和相关文献制备得到化合物51,MS(ESI)m/z[M+H]+:495.23。
实施例52
参照实施例3的实验方案和相关文献制备得到化合物52,MS(ESI)m/z[M+H]+:509.36。
实施例53
参照实施例3的实验方案和相关文献制备得到化合物53,MS(ESI)m/z[M+H]+:523.67。
实施例54
参照实施例3的实验方案和相关文献制备得到化合物54,MS(ESI)m/z[M+H]+:633.40。
实施例55
参照实施例3的实验方案和相关文献制备得到化合物55,MS(ESI)m/z[M+H]+:538.23。
实施例56
参照实施例3的实验方案和相关文献制备得到化合物56,MS(ESI)m/z[M+H]+:538.60。
实施例57
参照实施例3的实验方案和相关文献制备得到化合物57,MS(ESI)m/z[M+H]+:543.22。
实施例58
参照实施例3的实验方案和相关文献制备得到化合物58,MS(ESI)m/z[M+H]+:565.34。
实施例59
参照实施例3的实验方案和相关文献制备得到化合物59,MS(ESI)m/z[M+H]+:481.22。
实施例60
参照实施例3的实验方案和相关文献制备得到化合物60,MS(ESI)m/z[M+H]+:555.66。
实施例61
参照实施例3的实验方案和相关文献制备得到化合物61,MS(ESI)m/z[M+H]+:525.63。
实施例62
参照实施例3的实验方案和相关文献制备得到化合物62,MS(ESI)m/z[M+H]+:525.13。
实施例63
参照实施例3的实验方案和相关文献制备得到化合物63,MS(ESI)m/z[M+H]+:539.24。
实施例64
参照实施例3的实验方案和相关文献制备得到化合物64,MS(ESI)m/z[M+H]+:539.43。
实施例65
参照实施例3的实验方案和相关文献制备得到化合物65,MS(ESI)m/z[M+H]+:539.26。
实施例66
参照实施例3的实验方案和相关文献制备得到化合物66,MS(ESI)m/z[M+H]+:538.45。
实施例67
参照实施例3的实验方案和相关文献制备得到化合物67,MS(ESI)m/z[M+H]+:538.23。
实施例68
参照实施例3的实验方案和相关文献制备得到化合物68,MS(ESI)m/z[M+H]+:538.21。
实施例69
参照实施例3的实验方案和相关文献制备得到化合物69,MS(ESI)m/z[M+H]+:529.23。
实施例70
参照实施例3的实验方案和相关文献制备得到化合物70,MS(ESI)m/z[M+H]+:514.09。
实施例71
参照实施例3的实验方案和相关文献制备得到化合物71,MS(ESI)m/z[M+H]+:542.27。
实施例72
参照实施例3的实验方案和相关文献制备得到化合物72,MS(ESI)m/z[M+H]+:542.25。
实施例73
将3,5-二甲氧基苯乙酸73B(883mg,4.5mM)溶于二氯甲烷(25mL)中,加入EDCI(949mg,4.95mM)和三乙胺(752μL,5.4mM),搅拌半小时。加入1-(4-硝基苯基)哌嗪73A(933mg,4.5mM),继续反应,TLC监测反应完全,加入饱和碳酸氢钠水溶液,二氯甲烷萃取,合并有机层,分别用5%柠檬酸水溶液、水和饱和食盐水洗涤,无水硫酸钠干燥,浓缩干燥得到产品73C。
往产品73C中加入甲醇(20mL)、四氢呋喃(20mL)和10%钯/碳(150mg),在氢气条件下反应。经TLC监测反应完全,硅藻土过滤,浓缩滤液得产品73D
将化合物73D250mg(0.703mmol)溶解于20mL二氯甲烷中,然后加入三乙胺196μL(1.41mmol),室温下搅拌,再分批加入4-联苯磺酰氯73E214mg(0.844mmol),加毕,室温下反应过夜。有固体析出,抽滤,二氯甲烷洗涤,收集滤饼,干燥得到灰白色固体化合物73(222mg,产率55.2%)。1HNMR(400MHz,DMSO-d6)δ9.95(s,1H),7.86–7.81(m,2H),7.80–7.68(m,4H),7.53–7.46(m,2H),7.46–7.40(m,1H),7.01–6.92(m,2H),6.85–6.78(m,2H),6.42–6.33(m,3H),3.69(s,6H),3.67(s,2H),3.60–3.51(m,4H),3.02–2.90(m,4H).MS(ESI)m/z[M-H]-,570.0。
实施例74
将化合物73D250mg(0.703mmol)溶解于20mL二氯甲烷中,然后加入三乙胺196μL(1.41mmol),室温下搅拌,再分批加入4-氯磺酰苯甲酸74B171mg(0.774mmol),加毕,室温下反应过夜。反应液旋干,得到的残渣经硅胶柱层析(二氯甲烷:甲醇10:1)纯化得到白色固体,该固体用15mL二氯甲烷分散,室温搅拌1h,抽滤,二氯甲烷洗涤,收集滤饼,干燥后得到白色固体化合物74(85mg,产率22.4%)。1HNMR(400MHz,DMSO-d6)δ10.11(s,1H),7.94–7.87(m,2H),7.75–7.68(m,2H),7.67–7.60(m,2H),6.99–6.91(m,2H),6.49–6.32(m,3H),3.72(s,6H),3.70(s,2H),3.67–3.58(m,4H),3.09–2.98(m,4H).MS(ESI)m/z[M-H]-,538.1。
实施例75
将化合物73D250mg(0.703mmol)溶解于20mL二氯甲烷中,然后加入三乙胺196μL(1.41mmol),室温下搅拌,再分批加入丹酰氯75B228mg(0.844mmol),加毕,室温下反应过夜。反应液旋干,加入饱和碳酸氢钠水溶液和乙酸乙酯,萃取分层,收集有机相,无水硫酸钠干燥,旋干,得到的残渣经硅胶柱层析(石油醚:乙酸乙酯5:1)纯化得到浅黄色固体化合物75(134mg,产率32.4%)。1HNMR(400MHz,DMSO-d6)δ10.23(s,1H),8.45–8.40(m,1H),8.39–8.34(m,1H),8.11–8.06(m,1H),7.64–7.52(m,2H),7.29–7.22(m,1H),6.88–6.80(m,2H),6.76–6.68(m,2H),6.41–6.33(m,3H),3.69(s,6H),3.65(s,2H),3.57–3.46(m,4H),2.96–2.84(m,4H),2.81(s,6H).MS(ESI)m/z[M-H]-,587.2。
实施例76
参照以上实施例的实验方案和相关文献制备得到化合物76,MS(ESI)m/z[M+H]+:573.25。
实施例77
参照以上实施例的实验方案和相关文献制备得到化合物77,MS(ESI)m/z[M+H]+:541.16。
实施例78
参照以上实施例的实验方案和相关文献制备得到化合物78,MS(ESI)m/z[M+H]+:558.23。
实施例79
将1-(4-硝基苯基)哌嗪79A(1.036g,5mM)溶于甲醇(10mL)中,于0℃条件下慢滴入二碳酸二叔丁酯(1.24mL,5.4mM)的甲醇(5mL)溶液。经TLC监测反应完全,浓缩去除溶剂,用石油醚/乙酸乙酯(20/1)打浆,过滤,干燥得产品79B。
将以上产品79B溶于甲醇(15mL)中,加入10%钯/碳(150mg),在氢气条件下反应过夜。经TLC监测反应完全,硅藻土过滤,浓缩滤液得产品79C。
取以上产品79C(720mg,2.59mM)溶于二氯甲烷(15mL)中,加入三乙胺(542μL,3.89mM)和4-联苯磺酰氯(655mg,2.59mM),反应2.5h,经TLC监测反应完全,加入5%柠檬酸水溶液,用二氯甲烷萃取,饱和食盐水洗涤,无水硫酸钠干燥,浓缩,柱层析(石油醚/乙酸乙酯=2/1)得到产品79F。
将以上产品79F溶于甲醇(8mL)中,滴入4MHCl/甲醇(8mL),反应半小时,经TLC监测反应完全,浓缩得到产品79G。
将1-(4-甲氧基苯基)-1-环丙烷羧酸(69mg,0.36mM)溶于二氯甲烷(10mL)中,加入EDCI(71mg,0.37mM)和三乙胺(146μL,1.05mM),搅拌半小时。加入产品79G(150mg,0.35mM),继续反应,TLC监测反应完全,加入饱和碳酸氢钠水溶液,二氯甲烷萃取,合并有机层,饱和食盐水洗,无水硫酸钠干燥,浓缩,柱层析(二氯甲烷/甲醇=50/1)得到化合物79(45mg,产率22.6%)。1HNMR(400MHz,CDCl3)δ7.77(d,J=8.4Hz,2H),7.64(d,J=8.5Hz,2H),7.62–7.55(m,2H),7.48(t,J=7.3Hz,2H),7.46–7.39(m,1H),7.13(d,J=8.8Hz,2H),6.99(d,J=8.9Hz,2H),6.85(d,J=8.8Hz,2H),6.73(d,J=8.8Hz,2H),6.61(s,1H),3.85–3.53(m,7H),3.08(s,2H),2.82(s,2H),1.40(q,J=4.7Hz,2H),1.16(q,J=4.8Hz,2H)。
实施例80
将1-(4-硝基苯基)哌嗪80A(1.036g,5mM)溶于甲醇(10mL)中,于0℃条件下慢滴入二碳酸二叔丁酯(1.24mL,5.4mM)的甲醇(5mL)溶液。经TLC监测反应完全,浓缩去除溶剂,用石油醚/乙酸乙酯(20/1)打浆,过滤,干燥得产品80B。
将以上产品80B溶于甲醇(15mL)中,加入10%钯/碳(150mg),在氢气条件下反应过夜。经TLC监测反应完全,硅藻土过滤,浓缩滤液得产品80C。
取以上产品80C(832mg,3mM)溶于二氯甲烷(20mL)中,加入三乙胺(557μL,4mM)和丹酰氯(809mg,3mM),反应过夜。经TLC监测反应完全,加入5%柠檬酸水溶液,用二氯甲烷萃取,饱和食盐水洗涤,无水硫酸钠干燥,浓缩,柱层析(石油醚/乙酸乙酯=3/1)得到产品80D。
将以上产品80D溶于甲醇(10mL)中,滴入4MHCl/甲醇(10mL),反应半小时,经TLC监测反应完全,浓缩得到产品80E。
将1-(4-甲氧基苯基)-1-环丙烷羧酸(40mg,0.21mM)溶于二氯甲烷(5mL)中,加入EDCI(42mg,0.22mM)和三乙胺(84μL,0.6mM),搅拌半小时。加入产品80E(89mg,0.20mM),继续反应,TLC监测反应完全,加入饱和碳酸氢钠水溶液,二氯甲烷萃取,合并有机层,饱和食盐水洗,无水硫酸钠干燥,浓缩,柱层析(二氯甲烷/甲醇=40/1)得到化合物80(82mg,产率70.1%)。1HNMR(400MHz,CDCl3)δ8.52(d,J=6.4Hz,1H),8.34(d,J=7.7Hz,1H),8.07(d,J=7.1Hz,1H),7.66–7.57(m,1H),7.47–7.39(m,1H),7.23(s,1H),7.12(d,J=8.7Hz,2H),6.84(d,J=8.7Hz,2H),6.77(d,J=8.5Hz,2H),6.65–6.56(m,2H),6.46(s,1H),3.80(s,3H),3.78–3.52(m,4H),3.16–2.59(m,10H),1.43–1.32(m,2H),1.22–1.09(m,2H)。
实施例81
参照以上实施例的实验方案和相关文献制备得到化合物81,MS(ESI)m/z[M+H]+:576.20。
实施例82
将化合物82A300mg(0.916mmol)溶解于15mL二氯甲烷中,然后加入三乙胺140μL(1.01mmol),室温下搅拌,再分批加入化合物82B223mg(1.01mmol),加毕,室温下反应过夜。反应液有固体析出,抽滤,得到的滤饼经硅胶柱层析(二氯甲烷:甲醇10:1)纯化得到白色固体,该固体用25mL二氯甲烷分散,室温搅拌1h,抽滤,二氯甲烷洗涤,收集滤饼,干燥后得到白色固体化合物82(28mg,产率6.0%)。1HNMR(400MHz,DMSO-d6)δ9.96(s,1H),8.09–8.02(m,2H),7.82–7.74(m,2H),6.97–6.75(m,7H),3.73(s,6H),3.47(s,2H),3.09–3.02(m,4H),2.52–2.45(m,4H).MS(ESI)m/z[M+H]+,512.2。
实施例83
将5-甲酰基水杨酸83A(1.66g,10.0mM)溶于N,N-二甲基甲酰胺(30mL)中,加入碳酸钾(4.14g,30mM)和碘甲烷(2.18mL,35mM),室温过夜。TLC监测反应完全,加入水和乙酸乙酯萃取,合并有机层,用饱和食盐水洗涤,无水硫酸钠干燥,浓缩干燥得到产品83B。
将以上产品83B溶于二氯甲烷(150mL)中,加入1-(4-硝基苯基)哌嗪(1.9g,9.2mM),滴入醋酸(500μL),搅拌半小时后,分批加入三乙酰氧基硼氢化钠(3.18g,15mM),室温搅拌过夜。TLC监测反应完全,加入饱和碳酸氢钠水溶液,二氯甲烷萃取,合并有机层,分别用5%柠檬酸水溶液、水和饱和食盐水洗涤,无水硫酸钠干燥,浓缩干燥得到油状产品83C。静置2h后析出固体,用石油醚/乙酸乙酯(2/1)打浆,过滤,干燥得产品83C。
将以上产品83C溶于甲醇(100mL)中,于0℃条件下缓慢滴加一水氢氧化锂(2.1g,50mM)的水(25mL)溶液,升温至45℃,搅拌过夜。TLC监测反应完全,浓缩,加入水和乙醚萃取,用浓盐酸将水相pH调至2,析出固体,过滤,用水和乙酸乙酯洗涤,干燥得到产品83D。
往产品83D中加入甲醇(30mL)、四氢呋喃(30mL)和10%钯/碳(150mg),在氢气条件下反应。经TLC监测反应完全,硅藻土过滤,浓缩滤液得产品83E。
将化合物83E300mg(0.879mmol)分散于15mL水中,然后加入碳酸钾242mg(1.76mmol),室温下搅拌,再分批加入对甲苯磺酰氯83F184mg(0.967mmol),加毕,室温下反应过夜。反应液用2MHCl调节pH至3,有固体析出,抽滤,水洗涤,抽干,用混合溶剂(二氯甲烷:甲醇5:1)洗涤,收集有机溶剂洗涤液,旋干,经硅胶柱层析(二氯甲烷:甲醇10:1)纯化得到白色固体,该固体用15mL二氯甲烷分散,室温搅拌1h,抽滤,二氯甲烷洗涤,收集滤饼,该固体用水分散,滴加饱和碳酸钠溶解,再滴加稀盐酸调节pH至6,析出固体,抽滤,水洗涤,收集滤饼,干燥后得到白色固体化合物83(69mg,产率15.8%)。1HNMR(400MHz,DMSO-d6)δ9.75(s,1H),7.61–7.53(m,3H),7.47–7.39(m,1H),7.36–7.28(m,2H),7.11–7.05(m,1H),6.93–6.85(m,2H),6.82–6.73(m,2H),3.80(s,3H),3.47(s,2H),3.10–2.95(m,4H),2.52–2.40(m,4H),2.33(s,3H).MS(ESI)m/z[M+H]+,496.2。
实施例84
按照实施例83制备得到83E。将化合物84E300mg(0.879mmol)分散于15mL水中,然后加入碳酸钾242mg(1.76mmol),室温下搅拌,再分批加入丹酰氯84B283mg(1.05mmol),加毕,室温下反应过夜。反应液用2MHCl调节pH至3,有固体析出,抽滤,水洗涤,抽干,用混合溶剂(二氯甲烷:甲醇5:1)洗涤,收集有机溶剂洗涤液,旋干,经硅胶柱层析(二氯甲烷:甲醇10:1)纯化得到白色固体,该固体用15mL二氯甲烷分散,室温搅拌1h,抽滤,二氯甲烷洗涤,收集滤饼,干燥后得到白色固体化合物84(10mg,产率2.0%)。1HNMR(400MHz,DMSO-d6)δ10.18(s,1H),8.46–8.34(m,2H),8.12–8.05(m,1H),7.67–7.52(m,3H),7.44–7.37(m,1H),7.29–7.23(m,1H),7.10–7.03(m,1H),6.86–6.78(m,2H),6.75–6.66(m,2H),3.79(s,3H),3.42(s,2H),3.01–2.91(m,4H),2.81(s,6H),2.45–2.35(m,4H).MS(ESI)m/z[M+H]+,575.1。
实施例85
按照实施例83制备得到83E。将化合物83E300mg(0.879mmol)分散于15mL水中,然后加入碳酸钾242mg(1.76mmol),室温下搅拌,再分批加入2-萘磺酰氯85B239mg(1.05mmol),加毕,室温下反应过夜。反应液用2MHCl调节pH至3,有固体析出,抽滤,水洗涤,抽干,用混合溶剂(二氯甲烷:甲醇5:1)洗涤,收集有机溶剂洗涤液,旋干,经硅胶柱层析(二氯甲烷:甲醇10:1)纯化得到白色固体,该固体用15mL二氯甲烷分散,室温搅拌1h,抽滤,二氯甲烷洗涤,收集滤饼,干燥后得到白色固体化合物85(113mg,产率24.2%)。1HNMR(400MHz,DMSO-d6)δ9.97(s,1H),8.32(s,1H),8.13–8.05(m,2H),8.01(d,J=8.0Hz,1H),7.82–7.37(m,5H),7.17–7.05(m,1H),6.97–6.88(m,2H),6.81–6.71(m,2H),3.81(s,3H),3.36(s,2H),3.10–2.95(m,4H),2.52–2.37(m,4H).MS(ESI)m/z[M+H]+,532.2。
实施例86
将1-(4-硝基苯基)哌嗪86A(1.036g,5mM)溶于甲醇(10mL)中,于0℃条件下慢滴入二碳酸二叔丁酯(1.24mL,5.4mM)的甲醇(5mL)溶液。经TLC监测反应完全,浓缩去除溶剂,用石油醚/乙酸乙酯(20/1)打浆,过滤,干燥得产品86B。
将以上产品86B溶于甲醇(15mL)中,加入10%钯/碳(150mg),在氢气条件下反应过夜。经TLC监测反应完全,硅藻土过滤,浓缩滤液得产品86C。
取以上产品86C(720mg,2.59mM)溶于二氯甲烷(15mL)中,加入三乙胺(542μL,3.89mM)和4-联苯磺酰氯(655mg,2.59mM),反应2.5h,经TLC监测反应完全,加入5%柠檬酸水溶液,用二氯甲烷萃取,饱和食盐水洗涤,无水硫酸钠干燥,浓缩,柱层析(石油醚/乙酸乙酯=2/1)得到产品86F。
将以上产品86F溶于甲醇(8mL)中,滴入4MHCl/甲醇(8mL),反应半小时,经TLC监测反应完全,浓缩得到产品86G。
将产品86G(150mg,0.35mM)溶于二氯甲烷(8mL)中,加入三乙胺(146μL,1.05mM)和2-溴-4′-甲氧基苯乙酮(80mg,0.35mM),搅拌过夜。TLC监测反应完全,浓缩,柱层析(二氯甲烷/甲醇=50/1)得到化合物86(71mg,产率37.5%)。1HNMR(400MHz,CDCl3)δ8.07–8.00(m,2H),7.77(d,J=8.5Hz,2H),7.65(d,J=8.5Hz,2H),7.63–7.57(m,2H),7.49(t,J=7.3Hz,2H),7.43(d,1H),7.00(d,J=8.9Hz,2H),6.96(d,J=8.9Hz,2H),6.81(d,J=8.9Hz,2H),6.42(s,1H),3.90(s,3H),3.85(s,2H),3.30–3.18(m,4H),2.89–2.70(m,4H)。
实施例87
将1-(4-硝基苯基)哌嗪87A(1.036g,5mM)溶于甲醇(10mL)中,于0℃条件下慢滴入二碳酸二叔丁酯(1.24mL,5.4mM)的甲醇(5mL)溶液。经TLC监测反应完全,浓缩去除溶剂,用石油醚/乙酸乙酯(20/1)打浆,过滤,干燥得产品87B。
将以上产品87B溶于甲醇(15mL)中,加入10%钯/碳(150mg),在氢气条件下反应过夜。经TLC监测反应完全,硅藻土过滤,浓缩滤液得产品87C。
取以上产品87C(832mg,3mM)溶于二氯甲烷(20mL)中,加入三乙胺(557μL,4mM)和丹酰氯(809mg,3mM),反应过夜。经TLC监测反应完全,加入5%柠檬酸水溶液,用二氯甲烷萃取,饱和食盐水洗涤,无水硫酸钠干燥,浓缩,柱层析(石油醚/乙酸乙酯=3/1)得到产品87D。
将以上产品87D溶于甲醇(10mL)中,滴入4MHCl/甲醇(10mL),反应半小时,经TLC监测反应完全,浓缩得到产品87E。
将产品87E(134mg,0.30mM)溶于二氯甲烷(5mL)中,加入三乙胺(125μL,0.9mM)和2-溴-4′-甲氧基苯乙酮(69mg,0.30mM),搅拌过夜。TLC监测反应完全,浓缩,柱层析(二氯甲烷/甲醇=40/1)得到化合物87(64mg,产率38.2%)。1HNMR(400MHz,CDCl3)δ8.50(d,J=8.5Hz,1H),8.35(d,J=8.6Hz,1H),8.07(dd,J=7.3,1.1Hz,1H),8.05–7.99(m,2H),7.65–7.56(m,1H),7.41(dd,J=8.5,7.4Hz,1H),7.21(d,J=7.4Hz,1H),6.95(d,J=8.9Hz,2H),6.77(d,J=9.0Hz,2H),6.66(d,J=9.0Hz,2H),6.53(s,1H),3.89(s,3H),3.82(s,2H),3.26–3.07(m,4H),2.91(s,6H),2.77–2.68(m,4H)。
参比化合物
参照文献WO2010075469制备得到下列化合物,以下化合物的波谱学数据与文献一致:
参照文献WO2014150395制备得到下列化合物,以下化合物的波谱学数据与文献一致:
本发明部分化合物生物测试结果
一、荧光定量PCR实验检测药物对肝细胞PCSK9基因表达水平的影响
本实验目的是反映化合物对PCSK9基因表达的抑制作用,化合物对PCSK9基因表达的抑制作用越强烈,表明化合物潜在的降脂功效越强。
检测药物对HepG2细胞PCSK9mRNA的作用:
将HepG2细胞(ATCC),按每孔7×105细胞/孔的密度接种至6孔板,37℃,5%CO2培养过夜。次日,换液并加入待测药物和阳性药处理24小时。用Trizol试剂(Invitrogen)提取总RNA,RNase-FreeDNase(Promega)处理。每份样品取1ugRNA,用M-MLV逆转录酶(Promega)反转录成cDNA作为实时荧光定量PCR的模板。使用经过验证的PCSK9定量PCR引物、β-Actin定量PCR引物作为PCSK9及内参基因β-Actin的引物。用模板、引物、PowerSYBRGreenPCRMasterMix(Invitrogen)配制各样品的定量PCR反应体系,在定量PCR仪CFX96Real-TimePCRDetectionSystem(Bio-Rad)上按PCR仪器说明书要求进行实时荧光定量PCR反应,获得表达量数据。采用ΔΔCT法处理表达量数据,以β-Actin为内参,空白对照的PCSK9表达量设定为1,求得其余样品中PCSK9相对于对照的相对表达量(相对于对照的倍数),以此评估药物对肝细胞PCSK9基因表达水平的影响。
实验表明:本发明化合物,例如:3,6,8,10,11,12,14,15,16,17,19,22,23,24,25,26,27,28,29,32,33,34,35,38,39等,能够对PCSK9mRNA表达起到强烈的抑制作用。
二、LDL摄取率测试实验:
本实验的目的是在细胞水平上反映化合物对降低LDL的作用。LDL水平过高能致动脉粥样硬化。本实验从细胞水平直接检测肝细胞摄取LDL的能力,可直接反映化合物的降脂效果。
LDL摄取率细胞模型:
肝细胞表面表达LDL受体,具有摄取LDL的能力。在培养基中添加荧光物质Dil标记的LDL(Dil-LDL),在荧光显微镜下可观察到HepG2肝癌细胞将Dil-LDL摄取到细胞内。药物可使肝细胞表面LDL受体的量增多从而增强肝细胞对LDL的摄取能力,因此可用在显微镜下观察到的荧光强度评价样品对肝细胞摄取LDL能力的影响。
常规培养HepG2细胞(ATCC),按每孔2.5×104个细胞的密度接种至96孔板,37℃,5%CO2培养过夜。次日,弃上清,加入样品和阳性药处理20小时。弃上清,每孔加入含2μg/ml荧光性的Dil-LDL(Invitrogen)的新鲜培养基,在37℃,5%CO2条件下继续孵育4小时。弃上清,用PBS洗涤细胞2次,换新鲜培养基,在荧光显微镜(LeicaDMILLEDMicrosystems)下观察每孔细胞的荧光强度。以不加样品及Dil-LDL处理的正常细胞作为阴性对照。用在显微镜下观察到的荧光强度评价样品对肝细胞摄取LDL能力的影响,并加以分级,便于比较。分级方法如下:
-表示较正常细胞对照而言,无增加的荧光强度;
+表示较正常细胞对照而言,略微增加的荧光强度;
++表示较正常细胞对照而言,中等增加的荧光强度;
+++表示较正常细胞对照而言,强烈增加的荧光强度;
++++表示较正常细胞对照而言,非常强烈增加的荧光强度。
实验结果表明:本发明化合物能够显著地增强肝细胞对LDL的摄取能力。与文献WO2010075469和文献WO2014150395中具有代表性的化合物C1,C2,C3,C4,C5(结构式见上文)相比,使用较低的浓度本发明化合物处理的肝细胞表现出显著摄取LDL的能力,而参比化合物在低浓度处理过的肝细胞,对LDL几乎没有摄取能力。说明本发明化合物增加肝细胞摄取LDL的活性显著强于参比化合物C1,C2,C3,C4,C5。
三、化合物对ERK和AMPK信号途径的双重活化测试实验结果:
用本发明化合物对HepG2细胞处理,并检测ERK和AMPK的活化。
结果显示:较之未经处理的对照细胞而言,在经化合物处理的细胞中经磷酸化和活化的ERK和AMPK显著增加。其中包括化合物3,6,10,11,12,14,15,16,17,22,23,24,25,26,27,28,29,32,33,34,35,39等。
并且,采用高脂饲养诱导的胰岛素抵抗肥胖小鼠模型,本发明化合物具有降糖和降低体重的效果,具有明显改善糖耐量和胰岛素抵抗,增强胰岛素敏感性的特征。
另一方面,已有研究文献表明:AMPK的活化能够抑制mTOR和Akt的下游激酶,提示AMPK/Akt/mTOR可能是肿瘤治疗理想的靶点。已有研究文献中细胞实验和动物实验均提示,mTOR信号通路抑制后可以抑制肿瘤细胞的生长,本发明化合物活化的ERK和AMPK,可以进一步影响mTOR和Akt的下游激酶,提示本发明化合物可以进一步开发成为抗肿瘤药物。
四、SD大鼠模型体内降脂实验:
模型建立:定制高脂饲料饲养SD大鼠,正常组用普通大小鼠生长饲料饲养,4周后采集动物血清,检测指标变化。高脂饲料诱导的大鼠和正常组大鼠相比,血清中LDL-C、TC等含量有明显升高并具有统计学差异,证明高血脂模型建立成功。
急性毒性试验:采用单剂量连续给药7天,受试化合物在500mg/kg的剂量下,未表现出明显副作用。
试验组别和剂量设计:正常对照组,高脂模型对照组,辛伐他汀组(8mg/kg),化合物73组(20mg/kg),化合物80组(20mg/kg),化合物83组(20mg/kg),化合物86组(20mg/kg)。
动物数量:每组10只。
给药途径:口服灌胃。
给药频率:每天一次。
给药时间:4周。
血清指标测定:给药4周后,采取动物血液,进行测定。
测定结果归纳总结如图2,图3,图4,图5。
图2,图3,图4,图5的结果显示:本发明化合物73,化合物80,化合物83,化合物86均能显著降低模型动物的LDL-C和TC。图4和图5表明,高脂模型组和辛伐他汀组动物的谷丙转氨酶和谷草转氨酶水平有显著的升高,表明肝功能异常,但是,本发明化合物,在表现出显著体内降脂活性的同时,并没有增加谷丙转氨酶和谷草转氨酶水平,化合物73,化合物80,化合物83,化合物86组动物的谷丙转氨酶和谷草转氨酶水平与正常饮食组动物一致。说明本发明化合物在降脂的同时,提示并没有对肝脏造成损伤,但是辛伐他汀在降脂的同时,实验动物谷丙转氨酶和谷草转氨酶水平升高,说明服用辛伐他汀的模型动物肝功能受到了损伤,也揭示了他汀类药物明显的肝脏毒性。
五、SD大鼠模型非酒精性脂肪肝炎实验:
研究动物说明:本实验采用的研究动物为上述“SD大鼠模型体内降脂实验”使用动物,动物血清指标研究完成后,将动物处死并解剖,取动物肝脏组织,部分福尔马林固定,部分-80℃冷冻保存,固定超过48hr后进行病理切片染色(H&E染色、油红-O染色)检查。重点关注肝脏结构完整性、炎性细胞浸润与脂肪肝严重程度,并进行评分(评分标准:0级:正常;1级:<20%;2级:20-40%;3级:40-60%;4级:60-80%;5级:>80%)。结果见下表。
结果显示,高脂模型组与正常组相比,肝脏中脂肪细胞的体积明显增大,出现大泡性脂肪变性,脂肪的聚积严重破坏了肝脏的组织结构,造成肝脏空泡变性,并伴有大量炎性细胞浸润,以上现象表明,非酒精性脂肪肝炎造模成功。动物灌胃服用本发明部分化合物后,从空泡变性评分来看,化合物73,化合物80,化合物83,化合物86均对肝脏结构有一定的保护作用,由于脂肪细胞造成的肝脏损伤得到了一定修复,减小了空泡变性程度;化合物73,化合物80,化合物83,化合物86还能显著降低炎性细胞浸润,减少肝脏炎症程度,能减少脂肪的聚集和脂肪细胞体积增大,肝脏脂肪程度减轻。但是,辛伐他汀组动物肝脏解剖,其肝脏结构完整性、炎性细胞浸润与脂肪肝严重程度与高脂模型组一致,脂肪肝症状并没有缓解。本发明化合物73,化合物80,化合物83,化合物86均对肝脏组织有一定的保护作用,本发明化合物具有治疗脂肪肝的药用价值。
以上两项实验“SD大鼠模型体内降脂实验”和“SD大鼠模型非酒精性脂肪肝炎实验”,揭示了本发明化合物具有如下特点:
(1)、本发明化合物表现出降脂活性,不会影响肝脏正常功能。在安全剂量范围内,本发明化合物体现出体内降脂的活性,并没有引起大鼠转氨酶水平的升高,提示并没有对肝脏造成损伤。但是,辛伐他汀降脂药物,表现出降脂活性的同时,进一步使得动物转氨酶水平的升高,说明正常的肝脏功能受到了损伤,表现出明显的肝脏毒性。本发明化合物降脂但不影响肝脏功能的特点,在临床应用上,提示本发明化合物比他汀类药物具有较为显著的安全性优势。
(2)、本发明化合物对高脂模型动物脂肪肝症状具有潜在的治疗作用,而他汀类等降脂药并没有以上疗效。从“SD大鼠模型非酒精性脂肪肝炎实验”中可以看出,本发明化合物减少肝脏炎症程度,能减少脂肪的聚集和脂肪细胞体积增大,肝脏脂肪程度减轻,脂肪细胞造成的肝脏损伤得到了一定修复,减小了空泡变性程度。然而,辛伐他汀组动物肝脏解剖,其肝脏结构完整性、炎性细胞浸润与脂肪肝严重程度与高脂模型组一致,脂肪肝症状并没有缓解。
综合以上体内和体外药效学实验,可以看出,本发明化合物降脂作用机制,不同于现有上市降脂药物(例如:他汀类,贝特类等等),其优异降脂活性以及其良好的安全性特点,以及在脂肪肝治疗中的潜在治疗价值,有望成为广大心血管疾病患者获得良好治疗收益的新一代降脂药物。
Claims (17)
1.式V的化合物
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类;其中:
Y选自环烷基、杂环基、芳基、杂芳基,其中,
所述的环烷基、杂环基、芳基、杂芳基各自进一歩被一个或多个选自氢,卤,-OH,-NR′R″,-NO2,-Si(R′)3,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,-S(O)mR′,-S(O)nNR′R″,-OS(O)nR′,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″,-S(O)nNH(C=O)NR′R″,-NR′S(O)nR″,-NR′S(O)nNR′R″,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基的取代基所取代;
R1,R2,R3,R4,R5,R6,R7,R8独立地是氢,卤,经取代的或未经取代的硅基,氨基,硝基,氧代基,硫基,砜基,氰基,羰基,磺酰氧基,磷酰氧基,烷基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
M为氮原子,或者碳原子;
W为氮原子,或者碳原子;
K为-O-,-S-,-NH-,-CR5R6-,-C(O)-,-C(O)O-,-C(O)NH-,-SO2O-,-SO2-,-SO2NH-,-P(O)R5R6;
Z为-O-,-S-,-NH-,-CR5R6-,-C(O)O-,-C(O)NH-,-SO2O-,-SO2NH-,或者Z不为任何原子(即是,与Z相联的两个基团直接通过化学键连接);
环X为3~10元环,所述的3~10元环X选自环烷基、杂环基、芳基、杂芳基,其中,
所述的环烷基、杂环基、芳基、杂芳基各自独立地被一个或多个选自氢,卤,-OH,-NR′R″,-NO2,-Si(R′)3,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,-S(O)mR′,-S(O)nNR′R″,-OS(O)nR′,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″,-S(O)nNH(C=O)NR′R″,-NR′S(O)nR″,-NR′S(O)nNR′R″,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基的取代基所取代;
R′和R″独立的是氢或者经取代的或未经取代的烷基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基,
在-NR′R″,-C(O)NR′R″,-OC(O)NR′R″,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″中,其中NR′R″可以为4至20元含氮杂环基;
m=0,1,2;
n=1,2,3;
p=1,2,3;
q=0,1,2,3,4,5,6;
s=0,1,2;
t=0,1,2。
2.根据权利要求1的通式化合物化合物(V),其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中包括通式化合物化合物(VI),
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中:
R9,R10,R11,R12,R13,R14,R15,R16独立地是-H,卤,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R5,R6,R7,R8,Z,M,K,q,t,环X和环Y同权利要求1。
3.根据权利要求1的通式化合物化合物(V),其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中包括通式化合物化合物(VII),
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中:
R9,R10,R11,R12,R13,R14,R15,R16独立地是氢,卤,经取代的或未经取代的硅基,氨基,硝基,氧代基,硫基,砜基,氰基,羰基,磺酰氧基,磷酰氧基,烷基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R17,R18,R19,R20,R21独立地是氢,卤,-OH,-NR′R″,-NO2,-Si(R′)3,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,-S(O)mR′,-S(O)nNR′R″,-OS(O)nR′,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″,-S(O)nNH(C=O)NR′R″,-NR′S(O)nR″,-NR′S(O)nNR′R″,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基;
R5,R6,R7,R8,R′,R″,K,Z,环X,M,m,n,q,r同权利要求1。
4.根据权利要求3的通式化合物化合物(VII),其中,R9,R10,R11,R12,R13,R14,R15,R16独立地是-H,卤,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R17,R18,R19,R20,R21独立地是-H,卤,-OH,-NO2,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,取代的或未经取代的氨基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基,还选自包括:
R27选自苯基,C1-6烷基,环(C3-8)烷基,噻吩基,呋喃基,咪唑基,吡啶基,嘧啶基,哒嗪基,喹啉基,异喹啉基,苯乙炔基,苯甲基,苯乙烯基,萘基,取代氨基,吗啉基,哌啶基,N-甲基哌嗪基,四氢吡咯基,六氢吡啶基,樟脑烷基,对甲苯基,
其中,C1-6烷基任选被0至13个取代基取代,
噻吩基,呋喃基和咪唑基任选被0至3个取代基取代,
吡啶基任选被0至4个取代基取代,
嘧啶基和哒嗪基任选被0至3个取代基取代,
苯基任选被0至5个取代基取代,
喹啉基和异喹啉基萘基选任选被0至6个取代基取代,
萘基选任选被0至7个取代基取代,
以上的取代基选自:羟基,卤素,氰基,硝基,-COOH,羧酸酯基,取代或未经取代的氨基,硅基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R28选自氢,取代或者未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基。
5.根据权利要求1的通式化合物化合物(V),其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中包括通式化合物化合物(VIII),
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中:
R22,R23,R24,R25,R26独立地是氢,卤,-OH,-NR′R″,-NO2,-Si(R′)3,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,-S(O)mR′,-S(O)nNR′R″,-OS(O)nR′,-OS(O)nNR′R″,-OS(O)nNH(C=O)NR′R″,-S(O)nNH(C=O)NR′R″,-NR′S(O)nR″,-NR′S(O)nNR′R″,经取代的或未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基;
环Y,R1,R2,R3,R4,R5,R6,R7,R8,R′,R″,M,W,K,Z,m,n,p,q,s,t同权利要求1。
6.根据权利要求5的通式化合物化合物(VIII),其中,R22,R23,R24,R25,R26独立地是-H,卤,-OH,-NO2,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,取代的或未经取代的氨基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基,还选自包括:
R27选自苯基,C1-6烷基,环(C3-8)烷基,噻吩基,呋喃基,咪唑基,吡啶基,嘧啶基,哒嗪基,喹啉基,异喹啉基,苯乙炔基,苯甲基,苯乙烯基,萘基,取代氨基,吗啉基,哌啶基,N-甲基哌嗪基,四氢吡咯基,六氢吡啶基,樟脑烷基,对甲苯基,
其中,C1-6烷基任选被0至13个取代基取代,
噻吩基,呋喃基和咪唑基任选被0至3个取代基取代,
吡啶基任选被0至4个取代基取代,
嘧啶基和哒嗪基任选被0至3个取代基取代,
苯基任选被0至5个取代基取代,
喹啉基和异喹啉基萘基选任选被0至6个取代基取代,
萘基选任选被0至7个取代基取代,
以上的取代基选自:羟基,卤素,氰基,硝基,-COOH,羧酸酯基,取代或未经取代的氨基,硅基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R28选自氢,取代或者未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基。
7.根据权利要求1的通式化合物化合物(V),其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中包括通式化合物化合物(IX),
其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类,其中:
R9,R10,R11,R12,R13,R14,R15,R16,R17,R18,R19,R20,R21同权利要求3
R22,R23,R24,R25,R26同权利要求5;
R5,R6,R7,R8,K,Z,M,q同权利要求1。
8.根据权利要求7的通式化合物化合物(IX),其中:
K为-C(O)-,-SO2-,-SO2NH-,-P(O)R5R6;
R17,R18,R19,R20,R21,R22,R23,R24,R25,R26独立地是-H,卤,-OH,-NO2,-CN,-(CH2)0-6COOR′,-C(O)R′,-OC(O)R′,-C(O)NR′R″,-OC(O)OR′,-OC(O)NR′R″,取代的或未经取代的氨基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基,还选自包括:
R27选自苯基,C1-6烷基,环(C3-8)烷基,噻吩基,呋喃基,咪唑基,吡啶基,嘧啶基,哒嗪基,喹啉基,异喹啉基,苯乙炔基,苯甲基,苯乙烯基,萘基,取代氨基,吗啉基,哌啶基,N-甲基哌嗪基,四氢吡咯基,六氢吡啶基,樟脑烷基,对甲苯基,
其中,C1-6烷基任选被0至13个取代基取代,
噻吩基,呋喃基和咪唑基任选被0至3个取代基取代,
吡啶基任选被0至4个取代基取代,
嘧啶基和哒嗪基任选被0至3个取代基取代,
苯基任选被0至5个取代基取代,
喹啉基和异喹啉基萘基选任选被0至6个取代基取代,
萘基选任选被0至7个取代基取代,
以上的取代基选自:羟基,卤素,氰基,硝基,-COOH,羧酸酯基,取代或未经取代的氨基,硅基,烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基烷基;
R28选自氢,取代或者未经取代的烷基,烷氧基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳基烷基,杂环基或杂环基。
9.根据权利要求1~8的化合物,该化合物选自以下化合物,但不局限于以下化合物范围:
或其药用可接受的盐。
10.一种制备权利要求1所述通式(V)所示的化合物,其立体异构体,其互变异构体,其溶剂化物及其药用可接受的盐类的方法,其包括以下步骤:
以上的制备路线描述如下:X1和X2为该方案的起始物料,可以通过市售产品获得,或者根据文献报道的方法制备获得,X1和X2在一定的反应温度条件下,在一定的碱性试剂存在的条件下,通过偶联得到化合物V。
11.一种药物组合物,其包含权利要求1至9中任意一项的化合物和药学上可以接受的载体。
12.一种药物组合物,所述组合物包括给予需要治疗的患者有效治疗量的权利要求1至9中任意一项的化合物。
13.权利要求1至9中任意一项化合物在制备用于降低患者血浆和/或肝的脂类水平的药物中的用途。
14.权利要求1至9中任意一项化合物在制备用于治疗高脂血症,高胆固醇血症,高甘油三酯血症,肝脂肪变性和代谢综合征构成的疾病或病况的药物中的用途。
15.权利要求1至9中任意一项化合物在制备用于增加LDLR表达和/或降低PCSK9表达的药物中的用途。
16.权利要求1至9中任意一项化合物在制备用于减少LDL-胆固醇和/或血浆甘油三酯的药物中的用途。
17.根据权利要求1至9任意一项所述的化合物在制备用于治疗II型糖尿病,高血糖症,肥胖症,胰岛素抵抗症或者抗肿瘤药物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510001869 | 2015-01-01 | ||
CN2015100018692 | 2015-01-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105753817A true CN105753817A (zh) | 2016-07-13 |
Family
ID=56284315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511024626.7A Pending CN105753817A (zh) | 2015-01-01 | 2015-12-31 | 一类取代氮杂环衍生物及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN105753817A (zh) |
WO (1) | WO2016107602A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109232443A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 嘧啶酮衍生物、其制备方法及医药用途 |
CN111072639A (zh) * | 2019-12-13 | 2020-04-28 | 李丽丽 | Dpp-4抑制剂及其制备方法 |
CN111303120A (zh) * | 2020-03-14 | 2020-06-19 | 江巨东 | 一种盐酸法舒地尔的制备方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3337497B1 (en) | 2015-08-21 | 2023-07-12 | SRX Cardio, LLC | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity |
EP3337564A4 (en) | 2015-08-21 | 2019-01-23 | Portola Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR THE USE OF TETRAHYDROISOCHINOLINE SMALL MOLECULES FOR THE BINDING AND MODULATION OF PCSK9 PROTEIN ACTIVITY |
EP3337788A4 (en) | 2015-08-21 | 2019-03-27 | Portola Pharmaceuticals, Inc. | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE |
CN105214087B (zh) | 2015-10-29 | 2017-12-26 | 陈敏 | Pcsk9单克隆抗体在制备治疗炎症免疫性疾病药物中的应用 |
EA036851B1 (ru) | 2015-11-02 | 2020-12-28 | Янссен Фармацевтика Нв | [1,2,4]триазоло[1,5-a]пиримидин-7-ильное соединение |
US20190119236A1 (en) | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
AU2017353315B2 (en) | 2016-11-02 | 2021-09-16 | Janssen Pharmaceutica Nv | (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors |
JP7018944B2 (ja) | 2016-11-02 | 2022-02-14 | ヤンセン ファーマシューティカ エヌ.ベー. | PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン化合物 |
TWI764950B (zh) | 2016-11-02 | 2022-05-21 | 比利時商健生藥品公司 | Pde2抑制劑 |
CN116120261B (zh) * | 2022-11-30 | 2024-01-23 | 浙大宁波理工学院 | 一种3-[(4-磺胺哌嗪-1-基)甲基]苯甲酸类化合物的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5916739B2 (ja) * | 2011-04-15 | 2016-05-11 | 大塚製薬株式会社 | 6,7−ジヒドロイミダゾ[2,1−b][1,3]オキサジン化合物 |
-
2015
- 2015-12-31 CN CN201511024626.7A patent/CN105753817A/zh active Pending
- 2015-12-31 WO PCT/CN2015/100189 patent/WO2016107602A1/zh active Application Filing
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109232443A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 嘧啶酮衍生物、其制备方法及医药用途 |
CN109232443B (zh) * | 2018-10-29 | 2022-03-08 | 中国药科大学 | 嘧啶酮衍生物、其制备方法及医药用途 |
CN111072639A (zh) * | 2019-12-13 | 2020-04-28 | 李丽丽 | Dpp-4抑制剂及其制备方法 |
CN111303120A (zh) * | 2020-03-14 | 2020-06-19 | 江巨东 | 一种盐酸法舒地尔的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2016107602A1 (zh) | 2016-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105753817A (zh) | 一类取代氮杂环衍生物及其应用 | |
CN105753814A (zh) | 取代氮杂环衍生物及其应用 | |
CN105777632A (zh) | 芳环并氮杂环衍生物及其应用 | |
TWI805664B (zh) | Tlr7/8拮抗劑及其用途 | |
CN105814067B (zh) | 作为钠通道调节剂的吡啶酮酰胺的前药 | |
CN103119047B (zh) | 三环类蛋白酶体活性增强化合物 | |
CA3116729C (en) | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor | |
CN111171035B (zh) | 4-苯氧基苯基吡唑并嘧啶酰胺衍生物的制备方法和应用 | |
CN105777633A (zh) | 四氢异喹啉类衍生物及其应用 | |
CN106456795A (zh) | 靶向治疗学 | |
BRPI0805826B1 (pt) | compostos espiro-substituídos, composição farmacêutica e uso | |
AU2018251118A1 (en) | Pharmaceutical composition containing MOR agonist and KOR agonist, and uses thereof | |
JP2017538676A (ja) | ミトコンドリア透過性遷移孔(mtPTP)の小分子阻害剤 | |
CN105418601A (zh) | 四氢黄连碱衍生物及其应用 | |
CN104053439A (zh) | 1-(5,6-二氯-1h-苯并[d]咪唑-2-基)-1h-吡唑-4-羧酸的葡甲胺盐制剂 | |
CN105367485A (zh) | 用于预防和/或治疗中枢神经系统退行性失调的新颖组合物 | |
CN103059014A (zh) | 新型杂芳基氨基衍生物 | |
CN104024213A (zh) | 合成的表没食子儿茶素没食子酸酯(egcg)类似物 | |
CN103502219A (zh) | 作为治疗剂的新型小分子 | |
CN105367565A (zh) | 哌嗪(啶)环己基衍生物及其治疗精神神经疾病的应用 | |
TW202308634A (zh) | 使用sGC刺激劑之CNS疾病治療 | |
CN103360342B (zh) | 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用 | |
CN107141284B (zh) | 黄连碱类衍生物、其制备方法、药物组合物及抗肿瘤用途 | |
CN104603133A (zh) | 用于治疗癌症和免疫抑制的组合疗法 | |
CN101974016A (zh) | 酰胺类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160713 |